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ABSTRACT
Ventilator-associated pneumonia (VAP) is a common but preventable health-care
associated infection that affects up to 20% of mechanically ventilated adult patients, resulting in
estimated mortality rates ranging from 13% to 55% (Chahoud, Semaan, Almoosa, 2015; Melsen
et al., 2013). In an effort to reduce morbidity, mortality and related costs, the Centers for
Disease Control and Prevention (CDC) and the National Healthcare Safety Network (NHSN),
proposed ventilator-associated pneumonia prevention as a national patient safety goal. In 2014,
amid growing concerns that the subjectivity of existing definitions had led to inconsistent
reporting, thereby impeding efforts to reduce VAP, the CDC refocused surveillance efforts on,
the more broadly defined, ventilator associated events (VAE), which include VAP as well as a
set of related conditions. Hospitals have been inconsistent in their adoption of evidence-based
practice (EBP) to reduce the incidence of VAE. The purpose of this EBP project was to design,
implement, and evaluate the use of a comprehensive oral health intervention to: (a) reduce the
cumulative VAE rate at four facilities and (b) determine whether project adherence over a four
month period had an impact on VAE incidence rate reduction.
The Epidemiological Triangle of Infectious Disease and Everett Rogers’ Diffusion of
Innovation framework guided this multisite pretest-posttest study. The study introduced oral care
and biofilm elimination education for nurses, and an oral health assessment tool. Aggregated
VAE data was collected from each facility’s infection preventionist. The analysis involved pooled
mean comparisons of data in the pre-intervention and post-intervention periods. The data
showed a decrease in pooled VAE incidence rates of 1.8 per 1,000 ventilator-days, but this
difference was not statistically significant, Χ2 (1, N = 4,846) = .37, p = .54. There was also a
moderate correlation between documentation compliance and reduction of VAE rate (r = .4).
However, this correlation was not statistically significant (p = .6). These findings provide
preliminary evidence that routine oral assessment and timely intervention in MV patients are
useful components of comprehensive oral care practices to prevent VAE.
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CHAPTER 1
INTRODUCTION

Oral care is an important nursing intervention to reduce the risk of ventilator-associated
pneumonia (VAP) in the hospital setting. While the effectiveness of various oral care practices
has been studied in several patient populations, the most effective oral care solutions,
frequency, duration, and strategies for staff education remain unclear. The purpose of this study
is to answer the PICOT question: Among mechanically ventilated patients, how does the
implementation of an oral care assessment guideline combined with a mandatory staff
education program affect the incidence of ventilator associated events (VAE) when compared to
standard care over a four month period? This chapter will differentiate VAP from current
classifications of VAE, provide an overview of how VAP develops in endotracheally intubated
patients, and describe the significance of this project to prevent VAE in this population.
Background
Hospital acquired infections (HAI) encompass almost all clinically evident infections that
the patient acquires during the course of hospitalization and that do not originate from the
patient's original admitting diagnosis, according to Mehta et al. (2014) and Paitoonpong, Wong,
& Perl (2014). Within hours after admission, a patient's flora begins to acquire characteristics of
the surrounding environmental flora. Most HAIs become clinically evident after 48 hours of
hospitalization. Hospital acquired infections may also become evident after the patient's
discharge from the hospital. These are known as nosocomial in origin (Zimring et al., 2013).
Ventilator-associated pneumonia is a common HAI and is the leading cause of death
among hospitalized patients requiring mechanically ventilated airway support (Davis, 2006;
Klompas, Kleinman, & Murphy, 2014). A recent clinical survey suggests that the prevalence of
VAP is 9% to 27% among all intubated patients (Dudeck et al., 2011). However, according to
Choudhuri (2013), it is estimated that the prevalence of ICU-acquired VAP is 10% to 20% and
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results in crude estimated mortality rates ranging from 24% to 76%. These patients are twice as
likely to die during hospitalization, compared to mechanically ventilated patients without
pneumonia, according to the American Thoracic Society (2005). In another study by Klompas et
al., (2014), researchers concluded that the attributable mortality of VAP is estimated to be
approximately 10% but varies considerably for different kinds of patient populations. Although
there have been numerous advances in techniques for the management of mechanically
ventilated patients, VAP continues to impact morbidity, prolongs intensive care unit (ICU) length
of stay, and prolongs duration of ventilation. The estimated additional cost to treat VAP exceeds
$40,000 per occurrence (Davis, 2006; Klompas, Kleinman, & Murphy, 2014).
Until recently, the definition of VAP has been relatively unstandardized compared to
other types of HAI. The Centers for Disease Control and Prevention (CDC) indicated that true
incidence of VAP was difficult to determine due to the subjectivity of VAP surveillance (Klompas,
Kleinman, & Murphy, 2014; Magill et al., 2013). As a result, from 2011 to 2012, the CDC
convened a working group comprised of representatives from critical and respiratory care,
infectious diseases, healthcare epidemiology, and infection prevention professional societies to
develop a new approach to surveillance for mechanically ventilated patients in an attempt to
standardize VAP surveillance definitions (Klompas et al., 2014; Magill et al., 2013). The working
group made two recommendations: 1) to develop new definitions based on objective,
quantitative criteria to increase the reliability, reproducibility, comparability, and efficiency of
surveillance, 2) to broaden the scope of surveillance from pneumonia alone to encompass other
complications of mechanical ventilation. In 2014, the Centers for Disease Control and
Prevention (CDC) released an updated surveillance definition of VAP, which stratified VAP as
one of several ventilator-associated events (VAE). These events include ventilator-associated
conditions (VAC), infection-related ventilator-associated conditions (IVAC), possible VAP, and
probable VAP. All of these events are of interest to this study, as they represent preventable
adverse outcomes.
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Ventilator associated condition (VAC) is defined as a period of sustained respiratory
deterioration following a sustained period of stability or improvement while mechanically
ventilated, as evidenced by changes in the daily minimum fraction of inspired oxygen (FiO2) or
daily minimum positive end-expiratory pressure (CDC, 2014).
Infection-related ventilator-associated complication (IVAC) is triggered by the presence
of possible infection indicators concurrent with VAC onset. IVAC is said to have occurred in the
presence of abnormal temperature, below 36°C or above 38°C, or when white blood cell count
is less than 4,000 cells/mm3 or greater than 12,000 cells/mm3 and a new antibiotic is added and
continues for at least four days along with an oxygenation change (CDC, 2014).
Possible VAP is defined as occurring on or after calendar day three of mechanical
ventilation and within two calendar days before or after the onset of worsening oxygenation,
when one of the following criteria is met: 1) Gram stain evidence of purulent pulmonary
secretions, or; 2) a pathogenic pulmonary culture in a patient with IVAC (CDC, 2014).
Probable VAP is defined as occurring on or after calendar day three of mechanical
ventilation and within two calendar days before or after the onset of worsening oxygenation,
when one of the inclusion criteria in Table 1.1 is met (CDC, 2014).

PREVENTING VAE
Table 1.1
Inclusion Criteria for Probable VAP
Criterion

Requirements

1

Gram stain evidence of purulent pulmonary secretions
AND one of the following:


Positive culture of endotracheal aspirate, ≥ 105 CFU/ml or equivalent
semi quantitative result



Positive culture of bronchoalveolar lavage, ≥ 104 CFU/ml or equivalent
semi quantitative result



Positive culture of lung tissue, ≥ 104 CFU/ml or equivalent semiquantitative result



Positive culture of protected specimen brush, ≥ 103 CFU/ml or
equivalent semi-quantitative result

2

One of the following (without requirement for purulent respiratory secretions):


Positive pleural fluid culture (where specimen was obtained during
thoracentesis or initial placement of chest tube and NOT from an
indwelling chest tube)



Positive lung histopathology



Positive diagnostic test for Legionella spp.



Positive diagnostic test on respiratory secretions for influenza virus,
respiratory syncytial virus, adenovirus, parainfluenza virus.

4
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Statement of Problem
Despite advances in knowledge about management of mechanically ventilated patients,
VAP remains the most frequent infection among patients hospitalized in intensive care units
(ICU). It is a nosocomial infection that develops within 48 hours of establishing mechanical
ventilation and is caused by pathogens that were not present in the lungs at the time of (Davis,
2006; Horan, Andrus, & Dudeck, 2008).
Mechanical ventilation by means of endotracheal intubation is one of the most common
interventions implemented in the intensive care unit. Mechanical ventilation is also a mainstay of
supportive therapy for patients with acute respiratory failure. It is estimated that approximately
33% of patients admitted into the ICU are intubated with 24 hours of admission and account for
a disproportionately high share of total cost of ICU treatment (Dasta, McLaughlin, Mody, &
Piech, 2005). It is also estimated that ICU beds account for less than 10% of the total hospital
beds in United States. However, they account for one third of total inpatient costs, an estimated
national cost of $27 billion (Chalfin, Cohen, & Lambrinos, 1995; Dasta et al., 2005; Talmor,
Shapiro, Greenberg, Stone, & Neumann, 2006). One study conducted from October 2008
through December 2009, concluded that the mean hospitalization costs attributable to
mechanical ventilation was $59,770 and for mechanically ventilated adults diagnosed with VAP,
that cost was $99,598 (Kollef, Hamilton, & Ernst, 2012). This represents an additional cost of
$40,000.
Endotracheal intubation, a means of mechanical ventilation, is a necessary health care
intervention to support respiration in patients who are unable to maintain adequate tissue
oxygenation. The endotracheal tube bypasses several physiological barriers to respiratory tract
infection, including the lips, epiglottis, cilia and mucus secreting cells. As a result, VAP is a
potential outcome for nearly all patients who have undergone endotracheal intubation.
Etiology. Ventilator-associated pneumonia is caused primarily through the aspiration of
oropharyngeal pathogens into the lungs as well as through cross contamination of bacteria
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introduced into the oropharyngeal cavity by healthcare workers and microflora on the
endotracheal tube (Hutchins, Karras, Erwin, & Sullivan, 2009; Meherali, Parpio, Ali, & Javed,
2011; Nelson & Steinhoff, 2014, p. 562). Since the endotracheal tube bypasses normal
defenses by holding the mouth, epiglottis and vocal chords in open positions, pathogens are
able to pass into the lungs unopposed by normal defenses. Furthermore, ineffective oral care, in
conjunction with unintended contact with contaminated environmental items during
hospitalization, predisposes patients to nosocomial infections. Infection of the lower respiratory
tract typically arises from aspiration of secretions, colonization of the oral-gastric tract, or use of
contaminated equipment. Thus, the colonization of the oral cavity and the oropharynx directly
correlates with the causative agents of VAP.
Pathogenesis. The pathogens that commonly colonize pulmonary parenchyma in
mechanically intubated patients are endemic to the ICU environment (Klompas, Kleinman, &
Murphy, 2014). These microorganisms utilize a vast array of virulence factors, which are readily
transmitted between each other to induce inflammation, tissue destruction and cell death.
Furthermore, many microorganisms have developed mechanisms that allow them to evade
detection by the host immune system and penetration by antimicrobial medications (Thomas,
2013).
Endotracheal intubation is associated with increased accumulation of dental plaque, oral
debris, and biofilm; deterioration of mucous membranes, and colonization with respiratory
pathogens (Fourrier, Duvivier, Boutigny, Roussel-Delvallez, & Chopin, 1998; Needleman et al.,
2012). Consequently, the pathogenesis of ventilator-associated events is a function of the
myriad complex relationships between pathogen, host and environment. These relationships will
be further discussed in chapter 2 of this EBP project report.
Need for Project. The sites of implementation of this EBP project were four hospitals
within a medium sized health care system operating in the Midwest. Each of these hospitals has
a nursing procedure that identifies accepted and expected practices for providing oral care to
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patients with mechanical ventilation, which include the use of several evidence-based
interventions. These include mechanical brushing with chlorhexidine gluconate, head of bed
elevation, subglottic suctioning and periodic sedation vacations with weaning readiness
assessments.
Because there had been an increase in the incidence of VAP at one of these facilities,
the critical care nurse manager and clinical nurse specialist identified the need to audit
compliance with the facility’s oral care nursing procedure. They discovered that oral care using
the standardized supplies was not being performed as expected. Furthermore, while routine
nursing assessments of overall health status were being performed according to nursing policy,
oral health assessment was not included in the policy. Therefore, leaders at the four project
sites identified a clear need to provide staff education about oral care and to revise their oral
care protocol to include evidence-based interventions for routine oral health assessment.
Documentation of oral health assessment gives nurses a framework to evaluate the
extent of oral biofilm development to observe improvement or worsening of oral health over time
and to intervene in a timely manner to prevent the precursors to VAE. Biofilm can be effectively
fragmented by use of the force of mechanical brushing in conjunction with chlorhexidine
gluconate solution (Nicolosi, del Carmen Rubio, Martinez, González, & Cruz, 2014). When the
assessment is documented on a grid or chart, it facilitates the nurse’s recognition of trends
toward improving or worsening oral health (Ames et al., 2011; Ridley & Pear, 2008).
Purpose of the EBP project
The purpose of this EBP project was to implement an evidence-based oral care protocol
for mechanically ventilated adults to decrease the incidence of ventilator-associated events. The
goal of this EBP project was to answer the clinical question: Among mechanically ventilated
patients, how does the implementation of an oral care assessment guideline combined with a
mandatory staff education program affect the incidence of ventilator associated events (VAE)
when compared to standard care over a four month period?
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This project incorporated strategies to: (a) identify evidence-based practices to prevent
VAE using a protocol-based approach; (b) incorporate standardized oral health assessment into
the current facility-approved oral care nursing procedure; (c) educate critical care nurses
regarding facility-approved oral care procedures for patients with mechanical ventilation; (d)
provide ongoing education at the bedside to support critical care nurses’ use of the oral health
assessment tool; and (e) evaluate the effectiveness of staff oral care education and routine oral
health assessment on the incidence of VAE. Because oral plaque and biofilm tend to occur
together, observed reductions in plaque should correspond with reductions in biofilm (Nelson &
Steinhoff, 2014).
Significance of the project
Ventilator-associated events are common conditions in mechanically ventilated patients.
They are associated with clinically and economically devastating consequences, and the
incidence has not improved despite a growing body of evidence to support VAP prevention
interventions. Implementation of these guidelines using a translational science theoretical
framework is necessary to ensure their adoption in clinical practice.
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CHAPTER 2
REVIEW OF LITERATURE

Ventilator-associated events (VAE) encompass a variety of clinical conditions that occur
in people requiring mechanical ventilation, including infectious and non-infectious complications
of endotracheal intubation. Those susceptible to VAE represent a specialized population within
the health care system with risk factors for VAE that are avoidable or can be minimized through
evidence-based nursing interventions. This first section of this chapter synthesizes the current
literature regarding the relationship between hospital-acquired infections, such as VAE, and the
pathobiological mechanisms and clinical features of VAE from a pathophysiological perspective.
The second section of this chapter will apply the Epidemiological Triangle of Infectious Disease
to discuss complex factors such as agent, host, and environmental characteristics as they relate
to clinical causality in the development of ventilator-associated infections. Finally, the third
section of this chapter will propose that Everett Rogers’ Model of Diffusion of Innovations should
guide this project’s evidence-based nursing interventions to prevent ventilator associated
conditions and pneumonia among mechanically ventilated critically ill adults within the critical
care setting.
Summation of Current Literature
Healthcare associated infections (HAI), such as VAP, are common but preventable
infectious illnesses that often result in increased morbidity, mortality, and additional medical
care costs generated both in the hospital stay during which the preventable event occurs and
during subsequent health care encounters that might not have otherwise been necessary
(Pronovost et al., 2006). Since HAIs pose a significant health care problem to patients,
clinicians, organizations and governments, prevention of HAIs has attracted increased visibility
from regulatory agencies, healthcare organizations, healthcare personnel, and patient advocacy
groups (Affordable Care Act, 2010; American Thoracic Society, 2005; CDC, 2004, 2014; ICSI,
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2011; McKibben et al., 2005; Shi et al., 2013; Yokoe et al., 2014). Consequently, numerous
initiatives have been enacted at state and national levels, by the Centers for Medicare and
Medicaid Services (2013), to increase HAI transparency by requiring healthcare organizations to
report HAI rates. In addition, healthcare guidelines and policy initiatives are tying prevention of
HAIs to hospital reimbursement.
Ventilator-Associated Pneumonia
Ventilator-associated pneumonia (VAP) is one of the most common hospital-acquired
infections. It can develop in any patient on a ventilator, yet most occurrences are seen in
intubated or ventilated patients after 48 hours. In these cases, the ventilator itself, or the
process of intubation, acts as a source of direct entry for pathogens to gain access to the lungs
(Alhazzani, Smith, Muscedere, Medd, & Cook, 2013; Barbier, Andremont, Wolff, & Bouadma,
2013; Shi et al., 2013). Despite advances in techniques for the prevention and management of
VAP in mechanically ventilated patients, VAP remains the most frequent infection among
patients hospitalized in intensive care units. Ventilator-associated pneumonia is a nosocomial
infection that may develop following 48 hours of establishing mechanical ventilation mechanical
ventilation and is caused by pathogens that were not present at the time of intubation (Davis,
2006; Horan, Andrus, & Dudeck, 2008).
Ventilator associated conditions continue to occur as defined by the new specific ICD-9
code and are associated with a significant resource utilization burden, which underscores the
need for cost-effective interventions to minimize the occurrence of these complications. The true
incidence of VAP is difficult to determine as surveillance definitions have changed since January
2014. However, more recent clinical surveys suggest that the point prevalence is 9% to 27%
among all intubated patients (Dudeck et al., 2011). The newer classification of VAP as a
subtype of VAE will likely improve the accuracy of these estimates. According to Klompas,
Kleinman, and Murphy (2014), the mortality attributable to VAP is estimated to be approximately
10%, but varies considerably across ICU populations (Pereira et al., 2015).
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Based on the timing of onset, associated patient risk factors, and patient exposure, VAP
can be divided into early-onset or late-onset. Early onset VAP occurs in approximately one third
of cases usually within three to five days following intubation. The main cause is attributed to
pathogens (Staph. pneumoniae, H. influenzae and anaerobes of the oral cavity) with a favorable
pattern of antibiotic sensitivity. Late onset VAP occurs in approximately two thirds of cases and
is often caused by exposure to multidrug-resistant (MDR) pathogens such as Staph. aureus, P.
aeruginosa, Enterobacteriaceae and A. baumannii, which are endemic to most ICU units
(American Thoracic Society, 2005). Drug resistant pathogens are responsible for greater
morbidity, prolonged ICU length of stay (LOS), and longer duration of ventilation, with estimated
additional costs exceeding US$40,000 per occurrence (Kollef, Hamilton, & Ernst, 2012).
Although VAP is the most studied VAE type, it is important for policy and financial
reasons to focus on preventing all types of VAE. The next section will describe the
pathophysiological features of oral cavity, that when invaded, increase the host’s susceptibility
for the development of VAE.
Pathophysiology of the Oral Cavity
Mucosal Immune System. The development of oral biofilm is influenced by the
immunological milieu in the oral cavity (Cutler & Sluman, 2014; Prendergast, Kleiman, & King,
2013). The host’s mucosal immune system is of critical importance particularly due to its
adaptive nature in protecting the host’s mucosal surfaces. The mucosal immune system
consists of sentinel secondary lymphoid tissue, which is rich in antigen-presenting cells, CD4+ T
cells and B cells, which are present at the portals of entry to the body and extend to the
respiratory system, digestive tract, the genitourinary tract, eyes and mammary glands (Cole,
Wirth & Bowden, 2013). Secretory immunoglobulin A (SIgA) antibodies, primarily found on
mucosal surface layers and in exocrine secretions, are protective through a non-inflammatory
mechanism that neutralizes toxins and facilitates removal of endogenous oral microorganisms
which may be detrimental to the host due to unimpeded proliferation (Cole et al., 2013). This
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protective mechanism is carried out by salivary flow of secretions which block the adhesion or
aggregation to epithelia receptors on microbial cells thus inhibiting microbial growth and
mediating direct bacterial lysis (Cerrutti & Rescigno, 2008; Cole et al., 2013).
Oral Pharyngeal Structures. Motility of saliva is associated with the pharynx and
esophagus. From the mouth, the uppermost portion of the pharynx is the nasopharynx; it
extends from the posterior upper surface of the palate, posteriorly to the nasal fossa, to the
occipital bone (Sherwood, 2010, p. 463). The nasopharynx is surrounded by the
salingopharyngeal fold and tubal tonsils, which become inflamed when infected. It also contains
the adenoids and eustachian tube openings that provide drainage for lymphatic fluids into the
throat, nose, and ears (Sherwood, 2010, p. 463). The adenoids function to detect and destroy
pathogens entering the nasopharynx via the air. The uvula, a conic projection from the posterior
edge of the middle of the soft palate, is instrumental during swallowing and functions to close off
the nasopharynx to prevent foodstuff from back flowing into the nasal cavity (Sherwood, 2010,
p. 463).
Oropharynx. The next portion of the pharynx is the oropharynx. It is positioned behind
the oral cavity and extends from the posterior aspect of the soft palate to the epiglottis.
Additional oropharynx structures include the epiglottic vallecula, palatine and lingual tonsils, and
the epiglottis (Marieb & Mallatt, 1997). The oropharynx aids in swallowing, respiration and as an
immunological defense within the host. During swallowing, the epiglottis closes over the glottis
to prevent aspiration into the airway (Marieb et al., 1997). Immunologically, the palatine tonsils,
located laterally in the walls of the fauces, are responsible for T-cell activation following
microbiological exposure (Marieb et al., 1997; Sherwood, 2010).
Laryngopharynx. The inferior-most portion of the pharynx is the laryngopharynx. Like
the oropharynx, it facilitates digestion and respiration. It is lined with stratified squamous tissue
and extends from the hyoid bone to the larynx, inferior to the epiglottis. Continuous with the
esophagus, the laryngopharynx bifurcates into the larynx where sound is produced (Marieb &
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Mallatt, 1997; Sherwood, 2010). At the most inferior aspect of the laryngopharynx, the epiglottis
and vocal cords serve as physical barriers to potential pathogens entering the lower respiratory
tract.
Trachea. The trachea is lined with cilia and mucus-secreting goblet cells, which trap and
carry potential pathogens from the lower respiratory tract to the mouth where they can be
expectorated or swallowed (Marieb & Mallatt, 1997; Sherwood, 2010). The trachea bifurcates
into two bronchi that lead into the right and left lungs. Both lungs are contained within the rib
cage and are positioned superiorly to the diaphragm. In the patient without an artificial airway,
potential pathogens are unlikely to reach the lungs unless they are particularly virulent or the
host has nonfunctional protective mechanisms in the mouth, pharynx, larynx, and trachea due to
structural disease (e.g. throat cancer), immunosuppression, or mechanical failure of the
epiglottis from neurological dysfunction (e.g. cerebrovascular accident). The bronchial walls
contain mucus producing goblet cells and participate in the mucociliary transport system,
similarly to the trachea. However, excessive mucus production can easily obstruct airflow
through the relatively smaller bronchi. Coughing facilitates the removal of excessive mucus in
the host with an intact cough reflex.
Epithelium. The host and environment interface in two major ways, both of which offer
protection to the host from potential agents in the environment. The skin and nails cover the
human body and have a surface area of approximately two square-meters. The mucous
membranes, which line the gastrointestinal, respiratory, and urogenital tracts, cover a surface
area in excess of 400 square-meters (Cerrutti & Rescigno, 2008). Constant interactions with
micro- and macro-organisms occur on epithelial and mucosal portals of entry (e.g.
gastrointestinal tract, respiratory and urogenital tracts). Physiological interaction with these
microorganisms leads to colonization of epithelial and mucosal surfaces and this co-existence is
largely commensal (Cole, Wirth & Bowden, 2013; Hansen, Gulati, & Sartor, 2010). However,
when the protective functions of these tissues are compromised, exogenous bacteria invade the
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nutrient rich environment of the human body and cause infectious disease to develop, often with
deadly results (Hansen et al., 2010).
Artificial Airway. An artificial airway, such as an endotracheal tube or tracheostomy
tube, allows potential pathogens in the lower respiratory tract to evade mucociliary removal, and
the use of sedating medication (which is extremely common in patients who are mechanically
ventilated) or the presence of neurological impairment diminishes or inhibits the cough reflex. In
these patients, the only remaining natural defense mechanism against infection is the host
inflammatory response in the alveoli. This response consists of pre-existing alveolar
macrophages and the recruitment of neutrophils to the alveoli through cytokine and complement
activation and vasodilation of the alveolar capillaries. This host response is a powerful
mechanism to destroy invading pathogens, but it is nonspecific and can cause life-threatening
inflammatory injury within the alveoli. Clinical features of alveolar inflammation include
respiratory distress, cyanosis, leukocytosis, fever, hypoxia, respiratory acidosis, and respiratory
arrest. Radiographic evidence of widespread alveolar consolidation may be present. Oxygen
therapy, antimicrobial medications, anti-inflammatory medications, chemical paralysis, and a
variety of specialized mechanical ventilator settings can support respiration, but these therapies
have severe clinical and economic consequences. Because artificial airways bypass nearly all
host protective mechanisms, and the remaining mechanisms can be both ineffective and
counterproductive, prevention and early identification of oral cavity colonization is of paramount
importance in this population.
Endotracheal intubation is associated with increased accumulation of dental plaque, oral
debris, biofilms, deterioration of mucous membranes, and colonization by potential respiratory
pathogens (Fourrier, Duvivier, Boutigny, Roussel-Delvallez, & Chopin, 1998; Needleman et al.,
2012). Consequently, the pathogenesis of VAE is a function of the myriad complex relationships
between pathogens, host, and environment. Colonization of the oropharynx by potential
respiratory pathogens contributes to VAE. Further, ineffective oral care, in conjunction with
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unintended contact with contaminated environmental items during hospitalization, predisposes
patients to nosocomial infections. Infection of the lower respiratory tract typically arises from
aspiration of secretions, colonization of the oral-gastric tract, or use of contaminated equipment.
Thus, the colonization of the oral cavity and the oropharynx directly correlates with the causative
agents of VAE.
Oral Biofilm. The most common agents of VAE are the bacteria S. aureus, P.
aeruginosa, Enterobacteriaceae and A. baumannii. These species express specialized virulence
factors that enable a variety of survival advantages within the host, including: adherence to
biomedical devices, direct physical damage to cells lining the respiratory tract, nutrient
acquisition, resistance to antimicrobial medications, host immune factors, and development of
protective microbial communities called biofilms (Brennan et al., 2004; Dubey & Ben-Yehuda,
2011; Mohapatra, & Biswas, 2013).
Genetic and phenotypic variability within oral biofilm pathogens leads to biodiversity and
pathogenic genetic adaptation (Goulhen, Grenier, & Mayrand, 2003; Kumar, Mason, & Yu,
2013). This process occurs through cell-cell communication, gene transfer via conjugation and
plasmid exchange, and resistance to antimicrobial medications, heat, and gastrointestinal acid,
according to Kumar and colleagues (2013). Genetic regulation allows oral microflora to express
different characteristics within the oral cavity. This process confers advantages not only to other
co-existing bacteria, but also to the human host in some cases (Kumar et al., 2013).
Artificial Airways
Patients with artificial airways are uniquely susceptible to respiratory tract infections. In
patients without artificial airways, several structures and substances are present that prevent
lower respiratory tract infection. Saliva in the oral cavity provides several protective mechanisms
against infection, including physical removal of microorganisms through swallowing, a high
concentration of immunoglobulin A and complement, and a liquid environment that prevents
biofilm formation on dental enamel and oral mucous membranes. In addition, saliva also
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contains numerous non-specific protective factors such as lysozyme, lactoferrin, histatins,
mucins and peroxidases that have a protective function at mucosal surfaces. Moreover, salivary
flow buffers oral pH, thus neutralizing acid production in order to maintain dental and mucosal
integrity and facilitate oral particulate clearance (Cerrutti & Rescigno, 2008; Cole, Wirth &
Bowden, 2013; Hajishengallis, 2014).
Statistically, up to one-third of critically ill patients are susceptible to developing a lower
respiratory infection such as VAP (Armstrong & Mosher, 2011; DeKeyser Ganz et al., 2009). It
is not possible to determine which critically ill patients will develop hospital acquired pneumonia
as a result of bypassing their physiological protective structures without assessing their oral
cavity. It has been determined that poor oral health among mechanically ventilated patients
increases the bacterial virulence of oropharyngeal secretions that lead to the subsequent
development of nosocomial infections (Paju & Scannapieco, 2007) However, despite of the
American Association of Critical Care Nurses (AACN) recommendations advocating for oral
care, fewer than 44% of critical care nurses report brushing teeth (DeKeyser Ganz et al., 2009).
Therefore, translation of evidence-based oral care practice guidelines is important to improving
patient outcomes for critically ill, mechanically ventilated, care-dependent patients (CDC, 2014;
ICSI, 2011; Shi et al., 2013).
Oral Hygiene
Acutely ill patients are reliant upon nursing staff to perform oral hygiene. However,
studies report that staff are lacking in appropriate knowledge regarding the tools to adequately
and consistently assess and provide oral care (Ames et al., 2011; Chan, Lee, Poh, Ling, &
Prabhakaran, 2011; DeKeyser Ganz er al., 2009; Muscedere et al., 2011; Nicolosi et al., 2014;
Prendergast, Kleiman, & King, 2013; Richards, 2013; Ross & Crumpler, 2007). Oral care of the
critically ill hospitalized patient is an essential component of nursing care; therefore it is a
nursing responsibility. This care is particularly important to mechanically ventilated patients
when both disease and treatments lead to the deterioration of the oral membranes and teeth.
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This deterioration is primarily due to the marked decline in salivary secretions resulting from
disease processes and adverse effects related to medication regimens (Holmes & Mountains,
1993). Oral care is an important intervention that can augment the progression of microbial
proliferation in the mouth (Garcia et al, 2009). A thorough oral assessment is required to provide
clinicians with the patient’s baseline oral health status, monitor response to therapies, identify
new problems, and to decrease the risk of having commensal microflora with the oral cavity
from potentially proliferating to a pathogenic state thus increasing the risk of pneumonia as a
result of intubation or aspiration.
Oral Assessment Role
Human disease does not arise in a vacuum nor does it occur by chance. Epidemiology,
the study of the determinants and distribution of disease, forms the research basis of public
health interventions, including those that are implemented in health care facilities to prevent
nosocomial infections. Epidemiology is based on two fundamental principles that state that
disease does not occur at random and that disease is preventable (Nelson, 2014). Although
some diseases are genetic in origin, most human diseases, particularly infectious diseases such
as those included in ventilator-associated events, are caused by events, clinical conditions, host
characteristics, or a complex combination of these factors. Research methods, driven by an
epidemiological framework that links the host, an agent, and the environment, can be used to
evaluate the different factors or characteristics that favor the development, acquisition, and
transmission of infectious disease and its burden on populations. Furthermore, epidemiological
studies can be used to evaluate these multifactorial relationships in an effort to alter or intervene
in the disease cycle (Gange & Golub, 2014).
In summary, the mouth is a window to the overall health of the patient. Poor oral health
represents a general balance among host’s physiology, ongoing disease processes, and
adequate oral care aimed at preventing oral biofilm build-up, aspiration, and decompensation.
Oral deterioration and respiratory decompensation occurs when the balance is altered by
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changes in the interacting relationships among the stated factors. Prevention is concerned with
maintaining or initiating a balance of these factors to reduce the likelihood of oral infectious
processes that may lead to VAE development. The next section will describe the features that
agent, host, and environment as they relate to the Epidemiological Triangle of Infectious
Disease.
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Figure 2.1. Epidemiological Triangle
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• Behavioral Factors (Individual
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mineral structures)
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• Immunity (Host response to
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• Plaque, Enzymes, Minerals
• Bacterial Substrate
(Fermentable carbohydrates in
diet)
• Protective Factors (Flouride in
water, toothpase, dental care)
• Socioeconomic Factors
• Community & Cultural Norms
• Family and Social Support
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Agent Factors
• Bacterial Biofilm
• Specific Bacteria
(Staphylococcus, Escherichia coli,
or Pseudomonas aeruginosa)
• Other Pathogens (eg. yeast)
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Epidemiological Triangle of Infectious Disease

The Epidemiologic Triangle (Figure 2.1) is a conceptual framework that can be used to
model the transmission dynamics of an infectious disease (Friss & Sellers, 2014). The three
essential characteristics of the Epidemiological Triangle include the susceptible host, infectious
agent, and the environment. These three elements are depicted in Figure 2.1. The
Epidemiological Triangle describes disease by identifying the patterns of acquisition/exposure,
transmission, and risk factors inherent to a disease, in order to predict and thereby control or
prevent its transmission among a population within a particular setting (Friss & Sellers, 2014;
Gange & Golub, 2014). The epidemiological framework will guide the explanation of how agent,
host, and environmental factors jointly contribute to the development of VAE.
Agent
Within the epidemiologic triangle, an agent is a factor whose presence, absence, excess
or deficit is necessary for a particular disease or injury to occur. Bacteria, protozoa, and viruses
are examples of agents that have the potential to cause infectious disease depending on their
pathogenicity, virulence and infectivity. The pathogenicity of an organism is its ability to cause
disease (Nelson, 2014, p. 27). Virulence is the degree of pathogenicity within a group or species
of microorganisms as indicated by case fatality rates and/or the ability of the organism to invade
the tissues of the host (Nelson, 2014). Infectivity refers to the ability of a pathogen to establish
an infection (Nelson, 2014). These terms attempt to describe various aspects of the agent’s
impact on infectious disease. By measuring the pathogenicity, virulence, and infectivity of a
microorganism, clinicians can reduce the impact of the agent on the susceptible host (Gange &
Golub, 2014, p. 44).
Infective agents that exist and flourish within protective biofilms have been the source of
disease throughout evolutionary history. Biofilms affect the course and pathogenesis of a
number of systemic diseases including diabetes, cardiovascular disease, preterm birth, and
VAP (Igari, Kudo, Toyofuku, Inoue, & Iwai, 2014). Biofilms form tightly on biological and
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synthetic surfaces. This bacterial structure provides advantages and protection for species such
as S. aureus, P. aeruginosa, S. mutans and Enterobacteriaceae, from the host immune system
and from antimicrobial penetration (Chestre & Fagon, 2002). Biofilm formation enables
planktonic single celled microorganisms to adhere to each other and to a variety of moist
surfaces such as living tissues, indwelling medical devices, water system piping and natural
aquatic systems. This dynamic adherence process, of highly differentiated organisms, is
triggered in response to environmental changes, forming matrix-enclosed bacterial populations
in an effort to facilitate survival within adverse environments (Høiby, Bjarnsholt, Givskov, Molin,
& Ciofu, 2010; Nobbs, Jenkinson, & Jakubovics, 2011). After attachment, bacteria produce a
very sticky substance known as extracellular polymeric substance that traps nearby planktonic
bacteria and cements them into the biofilm, a process known as coadhesion.
As biofilm grows, nearby planktonic bacteria bind together through a process known as
coaggregation in preparation for adhesion to a larger microenvironmental matrix structure
(Huang, Li, & Gregory, 2011). These processes form three important survival advantages for
bacteria in the oral cavity. First, bacteria that are tightly aggregated to one another and adhered
within a biofilm are no longer influenced by the flow of saliva and cannot be swallowed or
otherwise removed from the oral cavity (Hannig & Hannig, 2009; Huang et al., 2011). Second,
bacteria in close contact with other bacteria can freely exchange plasmids and pathogenicity
islands that encode for more pathogenic virulence factors (Hannig et al., 2009; Hojo, Nagaoka,
Ohshima, & Maeda, 2009; Huang et al., 2011). In fact, even commensal non-pathogenic
bacteria in the oral cavity can become highly virulent within a biofilm with other highly virulent
bacteria. Third, the extracellular polymeric substance is impermeable to antimicrobial molecules
and soluble immune factors such as the complement system and immunoglobulins (Huang et
al., 2011). These important features of biofilms allow pathogens to thrive in the oral cavities of
patients with artificial airways.
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Aggressive and ongoing interventions that focus on removal of bacteria from the artificial
airway, dental enamel, and mucosal membranes are necessary to prevent the initial processes
of biofilm formation. Bacterial communication, within and between species, occurs through
molecular biochemical signaling within the oral biofilm matrix. The signal molecules, termed
autoinducers (AI), allow both monospecies and multispecies communities to synchronously
regulate gene expression (via a positive feedback loop), and therefore behavior, on a
community-wide scale (Huang, Li, and Gregory, 2011; Li & Nair, 2012; Mohapatra, & Biswas,
2013). The process of cell-cell communication in bacteria, known as quorum sensing (QS),
plays a critical role in shaping the composition of oral microflora by regulating gene expression
in a cell-density-dependent manner (Huang et al., 2011; Li & Nair, 2012). Bacteria use QS to
coordinate cellular functions such as biofilm formation, virulence, and antibiotic resistance,
based on the local density of the bacterial population, according to Li and Nair (2012). When a
biofilm becomes too densely populated, pathogens near the surface of the biofilm convert to
their planktonic form and leave the biofilm in search of a new location within the oral cavity or
respiratory tract.
These pathogens, which commonly colonize pulmonary parenchyma in mechanically
intubated patients, are endemic to healthcare settings as shown by Klompas and colleagues
(2014). In hospitals, biofilms form on durable medical equipment (i.e. mechanical ventilators)
enabling pathogenic organisms to persist as reservoirs and readily spread to patients. These
microorganisms utilize a vast array of virulence factors, which are readily transmitted between
each other within biofilms, to induce inflammation, tissue destruction, and cell death. Biofilm can
develop both in the community environment and in the healthcare setting. In hospitals, biofilms
form on medical equipment enabling pathogenic organisms to persist as reservoirs and readily
spread to patients. Inside the host, biofilms allow pathogens to subvert innate immune defenses
and are thus associated with long-term persistence. As these pathogens reproduce, they
exchange genetic material, leading to genetic and phenotypic variability, as well as antimicrobial
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resistance to infectious agents within the oral biofilm matrix (Huang, Li, and Gregory, 2011;
Kumar, Mason, & Yu, 2013).
Genetic variability is a measure of the tendency of individual genotypes in a population
to vary from one another by means of genetic exchange (Cummings & Lessler, 2014). In
essence, genetic variability leads to genetic biodiversity within a population (Frankham, 2005).
Genetic and phenotypic variability is essential for populations to adapt to environmental
changes. This is true in nature, as well as in the human mouth. In nature, two historical
occurrences illustrate this adaptation method. The genetic variability allowed pathogens to
spread and transmit over time to millions of people (Cummings et al., 2014). Furthermore,
because each of these adaptations is associated with a simultaneous change in antigenic
structure, the host’s immune system becomes less effective at recognizing the pathogen. This
leads to uninhibited microbial reproduction and damage to host cells.
In summary, the agent’s adaptability, virulence, resistance and stealth allows for its
pathogenicity. Pathogens have the ability to communicate and adapt to changing environments
allowing them to survive and develop highly virulent characteristics over time due to genetic and
phenotypical variability.
Host
A host is the individual susceptible to the infectious agent. In a health care setting, the
host may be a patient, visitor, or health care worker; although most of the emphasis of health
care associated infection prevention is placed on the patient. When the host has adequate
protection against infectious agents, it is less susceptible to infection. A host’s innate defenses
(i.e. normal flora, skin, epiglottis, sphincters, complement, neutrophils, macrophages) and
acquired defenses (e.g. antibodies, lymphocytes) provide this protection, but they can be
weakened by age, medical comorbidities, poor nutrition, genetic mutations, medications,
invasive devices or procedures, and the patient’s environment (Margolick, Markham, & Scott,
2014; Nelson & Steinhoff, 2014).
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Individuals with invasive devices, such as artificial airways, are at particularly high risk
for the development of health care associated infections once they are exposed to an infectious
agent. Invasive biomedical devices are inserted into the host to facilitate medical care, but they
bypass one or more primary lines of host defense. In the case of an artificial airway, the
epiglottis is maintained in an open position, which permits bacteria and yeast from the oral
cavity to migrate into the respiratory tract causing infection. Furthermore, an invasive biomedical
device provides a surface to which infectious agents, particularly bacteria, can adhere, form
biofilm, and more easily migrate into the lungs (Thomas, 2013).
Environment
The transmission of infectious agents from contaminated sources external to the host
can lead to the development of a hospital acquired infection (HAI). The environment plays an
important role in infectious disease epidemiology. A host’s environment is comprised of the
host’s physical surroundings and includes inanimate objects, air, water, and human contact
(Coffin et al., 2008; Mehta et al., 2014; Paitoonpong, Wong, & Perl, 2014). Particularly in the
intensive care unit, environmental factors, such as medical equipment, beds, furniture, and
other persons, harbor and promote the spread of pathogens (De la Fuente-Núñez, Reffuveille,
Fernández, & Hancock, 2013; Paitoonpong et al., 2014).
Many virulence factors expressed by pathogens, including adhesions, pili and fimbriae,
facilitate tight adherence of the pathogen to both inanimate and live surfaces. Moreover, some
bacteria can produce spores, which contain viable pathogen DNA and permit prolonged
pathogen survival within even the most hostile environmental surroundings.
Pathogens can be transmitted in a variety of ways through the environment, including
through direct physical contact, droplet nuclei in the air and direct inhalation of the organism.
Organisms such as those that cause VAE are spread primarily through direct physical contact.
Humans live in continuous interaction with their environment. Patients with an artificial airway,
especially if neurologically impaired or pharmacologically sedated, are particularly susceptible to
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environmental influences. In the critical care environment, these patients reside in a physical
environment that is heavily contaminated with a diverse ecology of highly virulent
microorganisms. Because these patients require frequent and usually hands-on care due to
their critical illness, they are often brought into direct physical contact with these
microorganisms.
Medications. Medications can increase the risk for infection in patients with artificial
airways. The use of highly potent antimicrobial medications to treat infections elsewhere in the
body can have important consequences in the pulmonary tract. First, broad-spectrum antibiotics
can have bactericidal effects on normal non-pathogenic flora that would otherwise offer the host
protection against the proliferation and migration of pathogenic flora. Second, inappropriate
antimicrobial use can lead to antimicrobial resistance. Anti-inflammatory medications, including
glucocorticoids and chemotherapeutic agents, suppress several immune mechanisms in the
host. In patients with artificial airways, these immune mechanisms are among the only defenses
available to prevent lower respiratory tract infections. When high doses of anti-inflammatory
medications are given, the alveolar inflammatory response is blunted and pathogens are
allowed to establish permanent colonies within the lung parenchyma. Guidelines have been
published that facilitate appropriate use of antimicrobials and anti-inflammatories (Bassetti,
Taramasso, Giacobbe, & Pelosi, 2012), but adherence to these guidelines has not been
evaluated. Regardless, medications are an important part of the host’s environment, particularly
in the critical care unit, and clinicians must be cautious to avoid inappropriate medication use.
Mechanical Ventilation. The mechanical ventilator and its circuitry are important
reservoirs of respiratory infection in the critical care unit. The ventilator must be properly
maintained based on the number of hours of use. Condensate forming within the breathing
circuit can also facilitate bacterial growth. The ventilator surfaces must be cleaned and the
breathing circuit and endotracheal tube must be discarded or appropriately sterilized between
patients. The breathing circuit and endotracheal tube are constructed of plastic and should be
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sterilized or replaced in accordance with the manufacturer’s recommendations. Mechanical
ventilators may also contain humidifiers that must be cleaned and refilled with water from a
suitable uncontaminated source. There is also a risk of trauma to the oral mucosa during
intubation or alveolar distention during positive pressure ventilation, either of which could further
compromise the host’s natural defenses.
Staff. Nurses, physicians, and respiratory care practitioners are important within the
mechanically ventilated host’s environment. The nurse has frequent and prolonged direct
contact with the host during bathing, repositioning, medication administration, and clinical
procedures. The physician has less frequent or prolonged exposure to the host than nurses, but
contributes significantly to the host’s risk for respiratory tract infections through initial placement
of the artificial airway, prescription of ventilator settings and medications, and ordering
diagnostic studies to monitor for evidence of infection. The respiratory care practitioner also has
frequent, though usually brief, direct contact with the host. However, physical contact between
the respiratory care practitioner and host involves several opportunities to introduce potential
pathogens into the ventilator circuit or other aspects of the host’s environment.
Clinicians involved in the care of mechanically ventilated patients must be
knowledgeable of the basic concepts of infectious disease epidemiology and proficient with their
application to this population (Gange & Golub, 2014). Using an epidemiological perspective, in
particular, the Epidemiological Triangle can be a useful strategy to frame quality improvement
projects related to the prevention of VAE. Evidence-based interventions addressing all three
aspects (i.e. agent, host, and environment) must be used to accomplish the goal of eradicating
VAEs in the mechanically ventilated population.
Literature Search Strategy
A comprehensive literature search occurred electronically to find the best evidencebased research relevant to oral health and VAE prevention. The following electronic databases
were searched: Cumulative Index to Nursing and Allied Health (CINAHL), Cochrane Database
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of Systematic Reviews, ProQuest, Medline, PubMed, Joanna Briggs Institute, and the National
Guideline Clearinghouse. The search was limited to scholarly articles, published in English,
since 2000 to ensure inclusion of classic articles. Search terms used for the literature search
included: oral care and ventilator-associated pneumonia prevention, oral biofilm elimination, oral
hygiene, oral assessment, and oral assessment tools. Boolean phrases “and” and “or” were
used between words to produce a larger volume of search results. The literature reviewed
included peer-reviewed journal articles, evidence-based practice articles, systematic reviews,
and meta-analyses. Additionally, the bibliographies for relevant research articles were consulted
to expand the literature search. Articles that were not clearly related to this EBP project,
editorials, expert opinions, and commentaries were excluded from the search.
Following the literature search, articles were reviewed for completeness and scope.
Duplicate studies were eliminated and all remaining articles were appraised to evaluate their
adequacy and transferability to this study. After thorough analysis, fifteen articles were selected
for this project.
Sources Examined for Relevant Evidence
All studies that were chosen for inclusion addressed the standard of oral care, use of
placebo or other products for oral care as control interventions and retained studies that
reported rates of ventilator associated pneumonia as outcomes. In CINAHL, out of a total of 130
possible articles four studies were appropriate for inclusion. A PubMed via EBSCO search
yielded nine articles. Out of those nine, three articles were appropriate to this study. The
remaining articles were discarded due to their lack of specificity to the subject under
investigation. In the Cochrane Database of Systematic Reviews, a search revealed 96 articles
and of those, eight meta-analyses addressed the clinical question. ProQuest yielded 13
potential sources based on the key terms. Of those, only one research article addressed the
clinical question. The remaining 12 articles did not meet inclusion criteria. Searches of the
Joanna Briggs Institute database resulted in seven articles. Out of seven, two were selected for
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inclusion into this study. Additionally, a search was done of the National Guideline
Clearinghouse database and it resulted in 14 guidelines. Only one evidence-based guideline
was appropriate for inclusion. The CONSORT Diagram in Figure 2.2 illustrates the flow of the
process used to appraise the evidence in the literature.
Following the literature search, nineteen articles were reviewed for completeness and
scope. Duplicate studies were eliminated and all remaining articles were critiqued. After
thorough examination, fifteen articles were selected for this project. The articles considered for
review included systematic reviews, meta-analyses, randomized control trials (RCTs), quasiexperimental studies, descriptive studies and a clinical practice guideline.
Critical Appraisal of Evidence
The Australian government’s National Health and Medical Research Council (NHMRC)
2005 classification system was utilized to appraise the level and quality of evidence for each
selected article. Out of the fourteen articles selected for inclusion, eight were meta-analyses of
RCTs (Level I); two were RCTs (Level II); one was a quasi-experimental study (Level III-1); and
four case studies with pre-test and post-test outcomes (Level IV). Ten of the articles were rated
“A” for overall high quality, three articles were rated at “B” for good quality, one article was rated
“C” for satisfactory quality, and none were rated “D” for poor quality. A summary of the articles
and their individual appraisal is presented on Table 2.1, which provides a summary of the
authors, date of publication, level of evidence rating, and key finding related to the proposed
EBP project.
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Table 2.1
Appraisal of Literature
Author(s)
Date

Levels of
Evidence

Alhazzani et

Level I

Key evidence and related findings


al., (2013)

Systematic review of six randomized control trials (RCT) comparing different
tooth brushing modalities (electric with manual) and chlorhexidine (CHX) use to
usual oral care.



In four trials, there was a trend toward lower VAP rates (risk ratio [RR], .77; 95%
CI, .50 to 1.21; p = .26). The only trial with low risk of bias suggested that
toothbrushing significantly reduced VAP (RR, .26; 95% CI, .10 to .67; p = .006).



Use of chlorhexidine antisepsis seems to attenuate the effect of toothbrushing on
VAP (p= .02).



One trial comparing electric vs. manual toothbrushing showed no difference in
ventilator-associated pneumonia rates (RR, .96; 95% CI, .47 1.96; p = .91).

Ames et al.,
(2011)

Level IV



Toothbrushing did not impact on length of ICU stay, or ICU or hospital mortality.



Evidence summary to identify the best available tools, the modified Beck Oral
Assessment Scale (BOAS) and the Mucosa-Plaque Score (MPS), for the oral
assessment and evaluation of oral hygiene as a means of reducing oral
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Levels of
Evidence

Key evidence and related findings

microflora that leads to the development of VAP.
CDC (2004)

Level I



CDC offers (clinical practice guidelines) recommendations in the prevention and
control of VAP.

Gastmeier &

Level I



Geffers, 2007

Systematic review of 15 RCTs that identified multi-module programs for reducing
VAP rates. The data lead to the conclusion that topical use of CHX for oral care
is beneficial and subglottic secretion drainage may lead to delayed onset of VAP.

Grap et al.,

Level II



(2011)

This RCT tested an early intervention involving a single dose application of CHX
by swab versus control (no swab) in an effort to reduce the incidence of VAP.



This study randomly assigned 145 trauma patients requiring endotracheal
intubation to the intervention (5 mL CHX) or control group. VAP (Clinical
Pulmonary Infection Score [CPIS] ≥ 6) was evaluated on study admission and at
48 and 72 hours after intubation.



A significant treatment effect was found on admission to 48 hours (p = .020) and
to 72 hours (p = .027).



The study concluded that an early, single application of CHX to the oral cavity
significantly reduces CPIS and thus VAP in trauma patients.
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Hutchins et

Level IV

31
Key evidence and related findings


al., (2009)

Descriptive study involving the implementation of an oral care intervention every
four hours on mechanically ventilated adult patients.



The use of an oral care intervention led to an 89.7% reduction in the VAP rate in
mechanically ventilated patients from 2004 to 2007.



The pre-implementation VAP rate in 2004 was 12.6 cases/1000 ventilator-days.
After the implementation of the oral intervention the VAP rates decreased to 4.12
VAP cases/days of ventilation x 1000 ventilator-days for May to December 2005,
to 3.57 for 2006, and to 1.3 for 2007.



The study concluded that the use of an oral care intervention led to a reduction
in the VAP rate among mechanically ventilated patients in this study.

Hillier et al.,

Level I



(2013)

This systematic review and meta-analysis of evidence comparing the effect of
oral care practices, oral hygiene products and oral protocols on VAP incidence
rates.



Review concluded that the implementation of an oral care protocol, ongoing
nurse education, and evaluation were important in reducing the incidence of
VAP.
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ICSI (2011)

Level I

32
Key evidence and related findings


Institute for Clinical Systems Improvement (ICSI) published evidenced based
VAP prevention guidelines in conjunction with the National Guidelines
Clearinghouse- (Guideline Summary NGC-8966). This systematic review
identifies the best available evidence for recommendations in the prevention of
VAP. The aims for this protocol are to eliminate VAP and to increase the use of
the VAP bundles and order sets in the management of mechanically ventilated
adult patients residing in the intensive care setting.

Koeman et al., Level II



(2006)

The objective of this randomized, double blind, placebo-controlled clinical trial
was to determine the effect of oral decontamination with CHX or CHX/COL on
VAP incidence and time to development of VAP.



This study enrolled 385 patients into three arms of the trial. Baseline
characteristics were comparable. The daily risk of VAP was reduced in both
treatment groups compared with placebo: 65% (hazard ratio [HR] = .352; 95%
CI, .160, .791; p=.012) for CHX and 55% (HR=.454; 95% CI, .224, .925; p= .030)
for CHX/COL.



The study concluded that oral decontamination with CHX or CHX/COL reduces
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the incidence of VAP. CHX/COL provided significant reduction in oropharyngeal
colonization with both gram-negative and gram-positive microorganisms,
whereas CHX mostly affected gram-positive microorganisms.
Muscedere et

Level I



Systematic review and meta-analysis of evidence comparing thirteen RCTs with

al.,

a total of 2442 randomized patients. The RCT involved mechanically ventilated

(2011)

adults patients and compared standard endotracheal tube use with and without
subglottic secretion drainage access and reported on the occurrence of VAP.


Of the 13 studies, 12 reported a reduction in VAP rates in the subglottic
secretion drainage arm.



The overall VAP RR was .55 (95% CI, .46-.66; p < .00001) with no heterogeneity
(I = 0%). The use of subglottic secretion drainage was associated with reduced
intensive care unit length of stay (-1.52 days; 95% CI, -2.94 to -.11; p = .03);
decreased duration of mechanically ventilated (-1.08 days; 95% confidence
interval, -2.04 to -.12; p = .03), and increased time to first episode of ventilatorassociated pneumonia (2.66 days; 95% CI, 1.06-4.26; p = .001). There was no
effect on adverse events or on hospital or intensive care unit mortality.
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Nicolosi et al.,

Level III-1

34
Key evidence and related findings


(2014)

Quasi-experimental study comparing the use instructor led oral hygiene (tooth
brushing) and oral rinses with .12% chlorhexidine gluconate (Group 1) to a
historical control group (Group 2) in the prevention of VAP among cardiovascular
surgery patients.



Dentist provided instruction and supervised oral hygiene with tooth brushing and
chlorhexidine oral rinses.72 hours prior to cardiovascular surgery.



There was a lower incidence of VAP (2.7% [95% CI .7-7.8] vs 8.7% [95% CI
4.9-14.7], P = .04) and a shorter hospital length of stay (9 ± 3 d [95% CI 8.5-9.5]
vs 10 ± 4 d [95% CI 9.4-10.7], P = .01) observed in the intervention group.



The risk for developing pneumonia after surgery was 3-fold higher in control
group (3.9, 95% CI 1.1-14.2).



The study concluded that supervised oral hygiene with chlorhexidine proved
effective in reducing the incidence of VAP.

Prendergast
et al (2013)

Level IV



A descriptive study evaluated the effectiveness of implementing two oral
assessment tools. The Bedside Oral Exam and the Barrow Oral Care Protocol
were used to guide oral assessments guide oral care for intensive care unit
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patients.


This study compared the incidence of VAP and the cost of oral care supplies
before and after implementation.



The intervention resulted in a decrease in the incidence of VAP from 4.21 to 2.1
per 1000 ventilator days (p =.04). Additionally, a cost savings of 65% was noted
on a monthly basis for oral hygiene supplies and nursing staff reported increased
satisfaction in providing oral hygiene with a combination of oral care products.



The study concluded a significant reduction in the incidence of VAP with the
Barrow Oral Care Protocol.

Richards

Level I



(2013)

Systematic review and meta-analysis of evidence assessed oral healthcare in
four domains for the purpose of comparison in the development of VAP. The four
domains were chlorhexidine (CHX mouth rinse or gel) versus placebo/usual
care, tooth brushing versus no tooth brushing, powered versus manual tooth
brushing and comparisons of oral care solutions



This systematic review included 35 RCTs (5374 participants) and classified the
trials according to their risk for bias, quality of evidence, and outcomes

PREVENTING VAE
Author(s)
Date

36

Levels of
Evidence

Key evidence and related findings

associated with a reduction in VAP.


Seventeen RCTs (2402 participants) provide moderate quality evidence that oral
care utilizing CHX mouth rinse or gel, as compared to placebo or usual care is
associated with a reduction in VAP (OR .60, 95% CI .47 to .77, P < .001, I(2) =
21%) A number needed to treat (NNT) of 15 (95% CI 10 to 34) was established.



There was no evidence of a difference between CHX and placebo/usual care in
the outcomes of mortality, duration of mechanical ventilation or duration of ICU
stay.



There was insufficient evidence to determine whether there was a difference
between CHX and placebo/usual care in the outcomes of duration of use of
systemic antibiotics, oral hygiene indices, microbiological cultures, caregivers'
preferences or cost.



Only three studies reported any adverse effects, and these were mild with similar
frequency in CHX and control groups.



Four RCTs (828 participants) compared oral hygiene without tooth brushing with
and without CHX, and was no evidence of a difference in the VAP rate (OR .69,
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95% CI .36 to 1.29, P = .24, I (2) = 64%).


This review concluded that effective oral care is important in reducing VAP
among ventilated patients in intensive care units. Oral healthcare that includes
either CHX mouthwash or gel is associated with a 40% reduction in the odds of
developing VAP in critically ill adults.

Ross et al.,

Level IV



(2007)

Implementation of an evidence based oral care program that focused on patient
safety, quality improvement, and improved patient outcomes (VAP reduction).



Implementation of an oral health assessment guide.



Concluded that an oral health assessment guide decreased median oral
assessment guide scores (pre-test: eleven, post-test: nine).

Shi et al.,
(2013)

Level I



Analysis (t-test) revealed a statistically significant difference (p= .0002)



The frequency of oral care documentation improved.



Systematic review and meta-analysis of evidence comparing the effects of oral
hygiene care in the form of mouthwashes, gel rinses, tooth brushing (or in
combination), and aspiration of secretions on the incidence of VAP among
critically ill mechanically ventilated patients from 1980 to January 2013.
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Thirty-five RCTs (5374 participants) were included in this review and were
classified according to their risk for bias, quality of evidence, and outcomes
associated with VAP reduction.



There were four main comparisons domains: or care solutions such as CHX
mouths rinse and CHX gel, versus placebo/usual care, tooth brushing versus no
tooth brushing, powered versus manual tooth brushing and comparisons of oral
care solutions such as saline, a weak povidone iodine solution, peroxide solution
and tap water.



There is moderate quality evidence from 17 RCTs (2402 participants) that CHX
mouth rinse or gel, when compared to usual care was associated with a
reduction in VAP (OR .60, 95% (CI) .47 to .77, P < .001, I(2) = 21%). This is
equivalent to a number needed to treat (NNT) of 15 (95% CI 10 to 34) indicating
that for every 15 ventilated patients in intensive care receiving oral hygiene
including chlorhexidine, one outcome of VAP will be prevented.



There is no evidence of a difference between CHX and placebo or usual care in
the outcomes of mortality (OR 1.10, 95% CI .87 to 1.38, P = .44, I(2) = 2%, 15
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RCTs, moderate quality evidence); duration of mechanical ventilation (MD .09,
95% CI -.84 to 1.01 days, P = .85, I(2) = 24%, six RCTs, moderate quality
evidence); or duration of ICU LOS (MD -.21, 95% CI -1.48 to 1.89 days, P = .81,
I(2) = 9%, six RCTs, moderate quality evidence).


One RCT compared use of a mechanical toothbrushing to manual toothbrushing.
The study provided insufficient evidence to determine the effect of intervention
on any of the measurable outcomes of this review.



A range of other oral care solutions were compared. There was weak evidence
that povidone iodine mouth rinse is more effective than saline in reducing VAP
(OR .35, 95% CI .19 to .65, P = .0009, I(2) = 53%) (two studies, 206 participants,
high risk of bias). However, due to the variation in comparisons and outcomes
among the trials, there is insufficient evidence concerning the effects of other
oral care solutions on the outcomes of interest.



The authors concluded that the provision of oral hygiene that includes CHX
mouth rinse is associated with a 40% reduction in the odds of developing VAP
among critically ill adults residing in the intensive care unit. There was no
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evidence of a difference in mortality, duration of mechanical ventilation or
duration of ICU length of stay.


There was weak evidence to suggest that povidone iodine mouthrinse is more
effective than saline in reducing VAP. There is insufficient evidence to determine
whether powered toothbrushing or other oral care solutions are more effective in
reducing VAP when compared to manual brushing with CHX.
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Figure 2.2
CONSORT Flow Diagram

Enrollment
Assessed for eligibility (n= 270)

Allocation
Studies with intervention (n= 248)
 Received allocated intervention (n=248)

Studies without intervention (n= 21)
 Received allocated intervention (n= 21)

Follow-Up








Received allocated intervention (n=24)
Did not receive allocation (partial articles,
lack of relevance, duplicates) (n= 224)
Excluded due to relevance (n= 3)

Received allocated intervention (n= 5)
Did not receive allocation (partial articles,
lack of relevance, duplicates) (n= 16)
Excluded due to relevance (n= 1)

Analysis
Analysed (n= 5)
 Excluded from analysis (relevance) (n=1)

Analysed (n= 24)
 Excluded from analysis (relevance)
(n= 9)

Final Selection

Final selection of evidence (n=15)
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Theoretical Framework

This section will discuss the theoretical framework that was chosen to inform this
evidence based practice change. A review of literature that represents an integrative review was
conducted and will be discussed.
Diffusion of Innovation
The theoretical framework chosen for this EBP project is Rogers’ Diffusion of
Innovations (DOI). This well-established model, with more than 5000 publications associated
with it since it was first published in 1962, is rooted in the works of Gabriel Tarde, a French
sociologist, criminologist and social psychologist, who plotted the original S-shaped diffusion
curve. DOI is of current importance because "most innovations have an S-shaped rate of
adoption" (Rogers, 1995). Over the past decades, the Diffusion of Innovation paradigm has
been implemented and validated by scholars from diverse disciplines and fields of study such as
anthropology, sociology, education, public health, nursing, medicine, communications, and
marketing, according to Rogers (2003).
Theory description
Nursing, like other allied health care fields, is a science-based profession. Research and
technology continually evolve and it is expected that corresponding care and treatments evolve
as well (Frantsve-Hawley & Meyer, 2008). New scientifically informed ideas, technologies, and
methods can be successfully implemented and adopted for a variety of systems through the use
of Rogers’ Diffusion of Innovations Theory (DOI). This theory fits well with this EBP project
because it provides a framework though which the adoption and use of innovation can effect
social change.
Diffusion of Innovation typically refers to a process by which a system adopts a new
practice. Rogers defines innovation as an ideal, or practice, that is perceived as new by a
person, unit, or organization. Diffusion, according to Rogers (2003), is the process by which an
innovation is communicated through certain channels over time among the members of a social
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system or organization (Frantsve-Hawley & Meyer, 2008). Rogers’ DOI (1995, 2003) proposes
that adopters of any new innovation or idea can be categorized based on the number of
standard deviations from the mean of the normal curve. It also proposes that each system’s
willingness and ability to adopt an innovation depends on their awareness, interest, evaluation,
trial, and adoption. Adoption occurs through subjective evaluation and communication regarding
the new innovation by those who have had success with the innovation (Frantsve-Hawley &
Meyer, 2008; Rogers, 2003).
Diffusion occurs through a five–step decision-making process. Rogers' five stages
include: knowledge, persuasion, decision, implementation, and confirmation. The first step,
knowledge, is influenced by needs and desires of the decision making unit as well as the prior
conditions such as traits and norms of the group (Rogers, 2003). Persuasion is determined by
how adopters will perceive (a) the need for innovation and (b) the characteristics of the new
practice (Frantsve-Hawley & Meyer, 2008; Simpson, 2011). If the innovation is of relative
advantage or perceived to be significantly better than current practice, well suited to the goals
and values of the organization (compatibility), easy to use and understand (simplicity), able to
be tried out first (trialability), and demonstrably beneficial (observability) then it is more likely to
be adopted. However, the decision stage takes into account the change and weighs the
advantages and disadvantages for using the innovation and decides whether to adopt or reject it
(Rogers, 2003). During the implementation phase, if the innovation is determined to be useful, it
is put into practice. The last stage is confirmation and it involves the evaluation of outcomes
related to the innovation and the reaffirmation that the implementation was the right decision.
The innovation must be widely adopted in order to be self-sustaining. The rate of
adoption is variable and is measured by the length of time required for a percentage of
individuals to adopt the innovation. The rate of adoption has to reach a critical mass, a point at
which enough persons have adopted the innovation for it to continue. Rogers suggests a
number of strategies that could be used to achieve the critical mass: (a) have a highly respected
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individual within a social network adopt and promote the innovation, (b) create a desire for a
specific innovation, (c) inject an innovation into a group of early adopters who would readily use
it, and (d) provide positive feedback and benefits for early adopters (Rogers, 2003).
Diffusion signifies a group phenomenon, which suggests how an innovation spreads
through the different adopter categories. The categories of adopters are: innovators, early
adopters, early majority, late majority and laggards. Among those, there are certain
characteristics of early adopters that should be noted. Rogers describes early adopters as
having a higher social status, being more financially stable, well-educated, and more socially
forward than late adopters (Rogers, 2003). Opinion leaders, Rogers suggest, derive
predominately from the early adopter category and exert influence over the others. Opinion
leaders are influential in spreading either positive or negative information about an innovation.
They have greater exposure to the mass media, are in contact with change agents, have a
higher social experience, better socioeconomic status, and are more personally innovative than
others (Rogers, 2003).
There are consequences to innovation. Both positive and negative outcomes are
possible when an individual or organization chooses to adopt or reject a particular innovation.
Rogers lists three categories for consequences: desirable or undesirable, direct or indirect, and
anticipated or unanticipated. The benefits of an innovation are the positive consequences, while
the costs are the negative. Costs may be direct or indirect. Direct costs are usually related to
financial burden while indirect costs are more difficult to identify. An example would be the need
to ‘staff up’ in order to implement an innovative change. Indirect costs may also be social, such
as social conflict caused by innovation (Rogers, 2003; Simpson, 2011).
Theoretical Framework Strengths and Limitations
The strengths of using Rogers’ DOI framework for this EBP project are readily apparent.
The DOI model continues to be applied successfully to different specialties with varying
problems and needs. The areas of application for these studies range from agriculture,
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engineering, mathematics, and nursing (Rogers, 1995; Simpson, 2011). This is largely due to
the model’s generalizability and transferability to applied research (Greenhalgh, Robert,
Macfarlane, Bate & Kyriakidou, 2004; Rogers, 2003).
Limitations of Rogers’ DOI framework include pro-innovation bias and individual-blame
bias (Rogers, 2003). Pro-innovation bias is the belief that an innovation should be adopted by a
system without the need of its alteration. The innovation's change agent has such strong bias in
favor of the innovation, that limitations remain inadvertently unnoticed. A second limitation is
individual-blame bias. The individual-blame bias is a tendency to blame individuals for their nonadoption. Some persons are laggards simply because they do not like change and are slow to
adapt to change. The responsible change agent must look beyond such individualistic
explanations to fully understand the rationale for systematic non-adoption. Instead, the change
agent should examine how the characteristics of the innovation might influence human behavior
toward adoption or rejection of a change effort.
Application of the Theoretical Framework to EBP Project
Everett Rogers’ ground-breaking framework has contributed to a greater understanding
of innovative change, including the variation in rates of adoption of innovations, and it has held a
broad scope of practical applications in the nursing and dental fields. Principles from the Rogers
theoretical framework are incorporated into this EBP project. Key concepts of the framework are
italicized in this section to highlight their application to the EBP project.
The innovation for this project is a standardized oral health assessment for orally
intubated patients in the ICU, which is an innovation for the project sites since they have
historically lacked a standardized oral health assessment. Two oral health assessment tools,
the modified Beck Oral Assessment Scale (BOAS; Appendix A) and the Mucosa-Plaque Score
(MPS; Appendix B) will be combined to form one standardized oral health assessment tool
specific for patients with endotracheal tubes. These tools have been shown to identify early
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evidence of oral biofilm development, which is an important early step in the development of
VAC.
Gaining approval and support of opinion leaders is an essential step in Rogers’ model.
The opinion leaders for this project initially consisted of the unit manager and unit clinical nurse
specialist (CNS) at one of the project sites, who embraced this project from the beginning.
During the project planning stage, clinical directors, infection preventionists, unit managers, and
CNS at all participating hospitals were contacted via email over a period of two months in order
to acquire their support, answer their questions, and discuss any concerns regarding the
benefits and value of the innovation for patient safety, cost reductions, and process
improvement. Rogers’ five steps of innovation diffusion are instrumental during these
discussions. Careful attention to knowledge building and persuasion is necessary throughout
project implementation and evaluation as adopters use the innovation alongside the myriad
distractions that are prevalent in the clinical setting. Anticipating these challenges, particularly
related to the ongoing need for persuasion, is essential for adoption. As advocates for patient
autonomy, clinicians need validation that the innovation fits within the contract for ethical
treatment of human research participants. As employees who report to hospital administrators,
clinicians need validation that their supervisors support the innovation, as well as the overall
project.
Clinicians and administrators alike must make the decision to adopt the innovation. For
administrators, this decision is made when providing the initial approval of the project for use in
the clinical department and each time they encounter difficulties in sustaining the innovation.
Clinicians make the decision to adopt the innovation initially when they are given the directive to
do so (either through education or institutional policy) and each time they are responsible for
acting on the innovation. Supporting the decision to adopt an innovation requires ongoing
education and persuasion, which can be accomplished through frequent interactions with
clinicians and administrators.
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Implementation of the innovation occurs as the adopter folds the innovation into their
usual patterns of care. In this project, implementation occurred when the ICU nurses became
more comfortable using the standardized oral health assessment scale using the correct
technique and at the correct frequency. This step requires active commitment from the
adopters, frequent contact with the project leader, and ongoing support from administrators.
Implementation can be measured through process measures, such as staff compliance with the
innovation. A downward trend in compliance may indicate the need for more knowledge about
the innovation, additional persuasion, and reaffirming the decision to continue implementation.
During the confirmation stage, the adopters are able to sustain the innovation with
decreasing levels of external support from the project leader or institutional supervisors.
Process indicators, such as innovation compliance, as well as outcome indicators, such as the
incidence rate of VAE, can be measured, statistically analyzed, and interpreted for significant
changes during this stage.
Strengths and Limitations of Rogers’ Framework in the context of the EBP project
The strengths of using Rogers’ DOI model for this EBP project are apparent. The DOI
model continues to be applied successfully to different specialties with varying problems and
needs. The areas of application for these studies range from agriculture (hybrid seed corn),
technology (modern math and engineering), and health care (antibiotic use, HIV/AIDS
prevention, oral health promotion) [Rogers, 1995; Simpson, 2011]. This is largely due to the
model’s generalizability and transferability to applied research (Greenhalgh, Robert, Macfarlane,
Bate & Kyriakidou, 2004; Rogers, 2003).
Everett Roger's DOI framework has contributed to a greater understanding of behavioral
change, including the variation in rates of adoption of innovations, and it has held a broad scope
of practical applications in the healthcare field. However, the investigator anticipated two major
limitations of the diffusion approach in the context of this EBP project. The first such limitation
was pro-innovation bias or the belief that everyone should unequivocally adopt the innovation as
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it exists. The investigator, as change agent, planned to mitigate pro-innovation bias by inviting
stakeholders to participate in giving feedback on the proposed innovation. This systematic
approach gave stakeholders an opportunity to voice their concerns and to understand how the
innovations would impact their workflow. A second anticipated limitation was individual-blame
bias or the tendency to blame individuals for their non-adoption. The investigator planned to
mitigate this bias by investigating how the characteristics of the innovation might affect laggards
or those resistant to change. The study not only included in-services for all staff nurses at the
four facilities regarding the rationale for and use of the innovation, but also reinforced the
change effort by rounding on a bi-weekly basis. Within this EBP project, the investigator planned
to mitigate potential limiting factors by inviting all stakeholders to explore the benefits and
consequences of adopting a new approach. With the inclusion of these planned mitigation
efforts, the DOI provided a framework that fit well with this EBP project.
The evidence suggests that the incidence of the various conditions that comprise VAE
can be reduced through the use of interventions that address the agent, host and environmental
characteristics of disease. A guiding framework is required in order to enhance the likelihood of
successful implementation and evaluation. The diffusion of innovation framework has attributes
that make it useful in guiding the selection and implementation of interventions to prevent
ventilator associated events among mechanically ventilated adults within the critical care
setting.
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CHAPTER 3
METHOD

The purpose of this project was to determine if an evidence-based standardized
oral health assessment, combined with a staff education program, would reduce the
incidence of ventilator associated events (VAE) among mechanically ventilated adults
admitted into the intensive care units at four Midwest community hospitals. The review of
literature supported a multifaceted intervention including routine structured oral
assessments and staff education to improve oral care techniques. This chapter
describes the population of interest, setting, and methods used for outcomes
measurement, data analysis, as well as the procedures for implementation of the
Evidence-Based Practice (EBP) project. Data management and protection of human
subjects is also addressed.
Participants and Setting
The sites for this EBP project were four community hospitals in the Midwest,
which are part of a multi-hospital not-for-profit organization. The settings of
implementation include four medical-surgical intensive care units at these facilities and
these units served as the units of analysis. These ICU areas admit critically ill patients at
least 18 years of age, and approximately one-half receive mechanical ventilation via
endotracheal tube. Because intervention and outcome data were not collected at the
patient-level, demographic variables were not measured. However, ventilator-days
(defined as the number of patients receiving mechanical ventilation at midnight census)
during the study period were collected from an administrative database.
Design and Outcome Variables
This EBP project utilized a single-group pretest-posttest design in which all
project sites began using the intervention simultaneously. The monthly VAE incidence

PREVENTING VAE

50

rate on each ICU was reported for a total of 13 months (nine months before
implementation, four months after implementation). Standardized surveillance definitions
for VAE were utilized for measurement of VAE incidence (Table 3.1). Briefly, incidence
was calculated as the number of VAE cases per unit per month divided by the number of
ventilator-days per unit per month, then standardized to a scale of 1,000 ventilator-days
(# cases / # ventilator-days * 1,000 ventilator-days), which is consistent with the scale
used in VAP prevention literature. The infection preventionist at each study site provided
aggregated data at the unit level for the outcome variables listed in Figure 3.1.
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Table 3.1
Outcome variables: National Healthcare Safety Network (NHSN) surveillance definitions
Variable

Operational Definition

Time

Defined in calendar months pre and post- implementation.

Patient-Days

Number of patients reported on the midnight census each day.

Ventilator-Days

Number of patients on a ventilator reported on the midnight census each day.

Ventilator Device

A device to assist or control respiration, inclusive of the weaning period, through a tracheostomy
or by endotracheal intubation.

Ventilator Device

Ventilator Device Utilization Ratio measures the proportion of total patient-days in which

Utilization Rate

ventilators were used on a given unit during a specified time period. It is calculated by dividing the
number of ventilator days by the number of patient days.

VAE Count

Number of VAE cases of patients on invasive mechanical ventilation; utilized standardized
surveillance definitions for VAE

VAE Rate

Total number of ventilator-associated events derived from a specific standard population during a
specified time period.

VAC Rate

Total number of observed healthcare-associated VACs among critically ill adult patients in the ICU
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Variable

Operational Definition

IVAC Rate

Total number of observed healthcare-associated IVACs among critically ill adult patients in the
ICU

Possible and

Total number of observed possible and probable VAP cases (with manifestations of purulent

Probable VAP

respiratory secretions or positive respiratory cultures) among critically ill adult patients in the ICU.

rate
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Intervention
Staff members that received the educational intervention were unit-based or float pool
staff registered nurses (RN) assigned to work in one of the study settings. The intervention had
two main components: (a) a standardized oral assessment and (b) an educational in-service for
staff registered nurses at the study units that focused on the objectives listed in Table 3.3.
Implementation of the intervention occurred at all sites over a 1-month period of time (October
2014), after which, post-intervention outcomes data collection commenced on a pre-determined
date at all sites.
The standardized oral assessment was comprised of two non-invasive oral assessment
tools: the Beck Oral Assessment Scale (BOAS) (Table 3.1) and the Mucosa-Plaque Score
(MPS) (Table 3.2). As described in Chapter 2 of this EBP report, both of these tools have good
internal consistency when used together. The BOAS and the MPS were incorporated into a
standardized oral assessment data collection form (Figure 3.0) to increase the accuracy of the
measured variables.
Additionally, the combined tool has excellent internal consistency as evidenced of a
Cronbach’s alpha of greater than .7.
The standardized oral assessment was to be performed every shift (defined for this
project as every 12 hours). All nurses received the same educational content, and time was
provided at the end of the in-service to answer questions.

PREVENTING VAE

54

Table 3.2
Beck Oral Assessment Scale (BOAS), modified

Lips

Gingiva and
oral mucosa
Tongue

Teeth

1
Smooth, pink,
moist,
and intact
Smooth, pink,
moist,
and intact
Smooth, pink,
moist,
and intact

Score
2
Slightly dry,
red
Pale, dry,
isolated
lesions
Dry,
prominent
papillae

3
Dry, swollen
isolated
blisters
Swollen red

Dry, swollen,
tip and
papillae are
red
with lesions
Moderate
debris
Scanty and
somewhat
thicker

4
Edematous,
inflamed
blisters
Edematous,
inflamed
blisters
Very dry,
edematous,
engorged
coating

Clean, no
debris
Thin, watery
plentiful

Minimal debris

Total Score

5
No dysfunction

6-10
Mild dysfunction

11-15
Moderate
dysfunction

16-20
Severe
dysfunction

Intervention
Frequency

Minimum care
every 12 h

Minimum care
every
8-12 h

Minimum care
every 8 h

Minimum care
every 4 h

Saliva

Increase in
amount

Covered with
debris
Thick and
ropy, viscid
or mucid

Note: Modified from Beck, S. (1979). Impact of a systematic oral care protocol
on stomatitis after chemotherapy. Caner Nursing, 2, 185-199.
Reprinted with permission from the Lippincott Williams & Wilkins,
International Society of Nurses in Cancer Care and the European Oncology
Nursing Society. Copyright Clearance Center Confirmation Number: 11266253
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Table 3.3
Mucosa-Plaque Score (MPS)
Criteria
Mucosa
Normal appearance of gingiva and oral
mucosa………………………………………………………………………..……………….1
Mild inflammation = slight redness and or hypertrophy/hyperplasia
Slight redness in some areas of the palatal mucosa; red spots indicating inflamed
salivary duct
orifices………………………………………………………………………………………….2
Moderate inflammation = marked redness and hypertrophy/hyperplasia of the gingiva,
which bleeds easily when pressure is applied and/or any of the following:
 Marked redness in large areas (≥2/3) of palate
 Marked inflammatory redness of the oral mucosa in sites other than the palate
 Presence of ulcerations
 Red and inflamed fibroepithelial hyperplasia …..…………………………………3
Severe inflammation = severe redness and hypertrophy/hyperplasia of the gingiva
 Spontaneous gingival bleeding
 Marked palatal granulations
 Inflamed oral mucosal areas that “break” easily and bleed under
pressure…...............................................................................................………4
Plaque
No easily visible plaque
……………………………………………………………………………………….……….…1
Small amounts of hardly visible
plaque……………………………………………………………………………….………….2
Moderate amounts of
plaque……………………………………………………………………………….………….3
Abundant amounts of confluent
plaque…………………………………………………………………………….…………….4
Score Greater than 5 reflects marked lack or oral integrity
Note: Based on data in Henriksen, B. M., Ambjornsen, E., & Axell, T. E. (1999). Evaluation of a
mucosal-plaque index (MPS) designed to assess oral care in groups of elderly. Special Care in
Dentistry, 19, 154-157. Silness, P., & Löe, H. (1964). Periodontal disease in pregnancy, II:
Correlation between oral hygiene and periodontal condition. Acta Odontologica Scandinavica,
22(1), 121-135. Reprinted with permission from the American Dental Association; American
Association of Hospital Dentists; Academy of Dentistry for the Handicapped; American Society
for Geriatric Dentistry. Copyright Clearance Center Confirmation Number: 11265179.

PREVENTING VAE

56

Figure 3.1 Oral Health Assessment Tool

ORAL HEALTH ASSESSMENT TOOL
FOR MECHANICALLY VENTILATED ADULTS IN ICU

BECK ORAL ASSESSMENT SCALE (BOAS)
Date:
Shift
N=11p-7a; D=7a-3p; E=3p-11p

N

D

E

N

D

E

N

D

E

N

D

E

N

D

E

N

D

E

N

D

E

Lips
Gingiva/Mucosa
Tongue
Teeth
Saliva
Total
Score
BOAS Score Legend
Lips
Gingiva & Oral
Mucosa
Tongue
Teeth
Saliva
Total Score:
Dysfunction
Intervention
Frequency

1
Smooth, pink, moist, intact
Smooth, pink, moist, intact

3
Dry, swollen isolated blisters
Swollen, red

4
Edematous, inflamed blisters
Edematous, inflamed blisters

Clean, no debris
Thin, watery, plentiful
5: None

2
Slightly dry, red
Pale, dry, isolated
lesions
Dry, prominent
papillae
Minimal debris
Increase in amount
6-10: Mild

Dry, swollen, tip and papillae are
red with lesions
Moderate debris
Scanty and somewhat thicker
11-15: Moderate

Very dry, edematous, engorged
coating
Covered with debris
Thick and ropy, viscid or mucid
16-20: Severe

>= Every 12 h

>= Every 8-12 h

>= Every 8 h

>= Every 4 h

Smooth, pink, moist, intact

MUCOSAL-PLAQUE SCORE (MPS)
Date:
Shift
N=11p-7a; D=7a-3p; E=3p-11p

N

D

E

N

D

E

N

D

E

N

D

E

N

D

E

N

D

E

N

Mucosa
Plaque
Total
Score

Mucosa

Plaque
Interpretation

MPS Score Legend
2
3
Mild inflammation: slight
Moderate inflammation: marked
redness and or
redness and hypertrophy/hyperplasia
hypertrophy/hyperplasia.
of the gingiva, which bleeds easily
Slight redness in some
when pressure is applied and/or any
areas of the palatal
of the following:
mucosa; red spots

Marked redness in large areas
indicating inflamed salivary
(≥2/3) of palate
duct orifices

Marked inflammatory redness
of the oral mucosa in sites
other than the palate

Presence of ulcerations

Red and inflamed
fibroepithelial hyperplasia
No easily visible plaque
Small amounts of hardly
Moderate amounts of plaque
visible plaque
A total score greater than 5 reflects a significant lack of oral integrity.
1
Normal appearance of
gingiva and oral mucosa

4
Severe inflammation:
severe redness and
hypertrophy/ hyperplasia of
the gingiva:

Spontaneous gingival
bleeding

Marked palatal
granulations

Inflamed oral mucosal
areas that “break”
easily and bleed
under pressure
Abundant amounts of
confluent plaque

D

E
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Implementation Plan

Everett Rogers’ DOI framework served as a useful map for planning this EBP project.
Table 3.3 provides detailed descriptions of how each of these stages influenced innovation
adoption in this EBP project.
Knowledge of the local problem with VAE had already been established by the clinical
directors, unit managers, IP, and CNS, but there was a knowledge gap regarding the solution to
this problem. Therefore, the first step in this project was to explore with the clinical stakeholders
what the barriers were to achieving their goal of having no VAE in their facilities. One such
barrier was a lack of standardized oral health assessment practices, and another was poor
compliance to evidence-based procedures for oral care of patients with mechanical ventilation.
While the clinical stakeholders perceived both of these barriers to be important, they agreed that
the emphasis for this project was to develop, implement, and evaluate a standardized oral
health assessment procedure. Clinical stakeholders decided to facilitate this project with the
expectation that any staff education would also include a review of the approved standards of
care for oral hygiene.
After agreeing to the project aims, timeline, and responsibilities of the clinical sites and
EBP project leader, the project was planned with substantial input from the clinical stakeholders
and the EBP project advisor. After achieving consensus on project methods, approval to
conduct human subjects research was obtained from the institutional review board (IRB) at both
the academic institution at which the EBP project leader was enrolled as a student and at the
clinical sites. Obtaining these approvals before approaching clinical staff about the project was
vital to the successful adoption of the project because it demonstrated to the clinical staff a
commitment to protect the autonomy of each ICU patient, even though they were not
individually required to provide informed consent to participate in the project. A plan was also
developed to establish on-site and on-call availability of the project leader throughout the
decision and implementation phases.
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The EBP project leader arranged times at each site to deliver intervention training to the
nursing staff. Upon completion of the program, nursing staff were expected to: (a) explain the
significance of oral health assessment in patients with mechanical ventilation, (b) perform a
standardized oral health assessment for patients with mechanical ventilation, and (c) perform
site-approved oral hygiene for patients with mechanical ventilation. The educational program
consisted of a brief oral presentation during a regularly scheduled unit staff meeting, a handout
that provided further details about the intervention, a project binder with additional information
about VAE prevention, a one-page flyer that explained how to complete the standardized oral
health assessment procedure, and a printed poster describing various VAE prevention
strategies.
Unit-based leaders at each project site, including nurse managers, charge nurses, and
clinical nurse specialists, were recruited as change champions to facilitate and motivate staff
nurses to utilize the standardized oral health assessment tools. These unit leaders also
implemented “train-the-trainer” sessions at each project site. The nurse manager and CNS at
each facility identified a site-specific plan to distribute data collection forms, display the
educational poster, and store completed data collection forms until they could be retrieved for
data entry. Staff training occurred from October 1st, 2014 through October 31st, 2014. The unit
leaders, IP, and clinical nursing director agreed to implement the project on November 2nd,
2014.
Oral assessment methodology
Nurses will receive initial training on the use of the oral assessment tools during a unitbased educational session. Although routine oral care was being performed on mechanically
ventilated patients, staff had not consistently assessed for evidence of biofilm growth within the
mouth of mechanically ventilated patients. The innovation was conceptually embraced by the
nurse manager, the regional education manager, and the regional chief nursing officer (CNO).
The investigator proposed an in-service in which she would discuss each facility's VAE/VAC
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prevention protocol with the addition of teaching nurses a systematic way to assess the
intubated patient's oral health status. The initiative was implemented at four Midwestern
hospitals.
On, November 2nd, 2014, follow-up phone calls, reiterating the importance of the EBP
project, were made to unit managers, unit team leaders, or charge nurses as a reminder of the
implementation date on the following day. The EBP project leader began bi-weekly site visits to
reinforce or provide additional training, as needed, to promote intervention adherence among
unit staff. These site visits were performed on all shifts for several weeks and then were
performed exclusively on the day (7:00 A.M. to 7:00 P.M.) shift to ensure availability to the nurse
managers and CNS, who primarily worked on this shift. The decision to change the schedule for
site visits was made based on feedback from the nurse manager and CNS at these sites.
During the implementation of the study, when the patient arrived to the critical or
intermediate care areas, the staff nurses assessed the oropharyngeal and mucus membranes,
teeth, and artificial airway for risk factors and signs and symptoms of deterioration or infection.
The BOAS and MPS were quantified either upon patient intubation or arrival to the critical care
unit, whichever came first. Patients at low risk for developing VAE received preventive
measures, including mechanical tooth brushing and chlorhexidine application at least every 12
hours. Those patients who were revealed to have mild to severe oropharyngeal and mucus
membrane dysfunction had mechanical oral care more frequently, per institutional policy.
Additionally, primary care providers were instructed regarding the potential severity of the of
oropharyngeal and mucus membrane dysfunction in order to facilitate a more collaborative
treatment approach for critically ill patients at high risk for VAE development.
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Table 3.4
Application of Rogers Diffusion of Innovation
Rogers Stage of Change
Acquisition of Knowledge

EBP Project Action Step





Change in NHSN surveillance definitions of VAE/VAC/VAP
Study site acknowledgement of inconsistent oral care in patients with
endotracheal tubes
Email sent to regional director of critical care and infection prevention at study
setting explaining the proposed EBP project focusing on prevention of VAP
Meeting with site leaders to explain the project purpose, scope, and proposed
methods

Persuasion




Obtained strong support of leaders at study sites
Identified change champions at each study site

Decision-Making





Administration authorized the practice change at all study sites
Change champions were educated on the study purpose and methods
Feedback sought from change champions for ways to maximize study
procedure adherence among staff

Implementation



EBP project leader attended departmental staff meetings to explain the study
purpose, how to perform the standardized oral assessment, reinforcement of
facility VAP prevention protocol, and how to submit the completed oral
assessment tool to the EBP project leader
Bi-weekly project leader site visits to support implementation
Meetings with site leaders and change champions as needed to clarify project
goals and methods



Confirmation



Standardized oral assessment will be included in the next revision of regional
VAP prevention protocol
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Data Analysis Plan
Ventilator-associated events were counted each month at all project sites and
standardized across sites using ventilator-days. The incidence rate of VAE per month was
calculated for each site, along with the incidence rate of all VAE subtypes (i.e. VAC, IVAC,
possible VAP, and probable VAP). To test the null hypothesis that there was no statistically
significant difference between VAE incidence from pre-intervention to post-intervention, a 2x2
contingency table was constructed for each site using data from all four project sites with VAE
(present or absent) on one axis and implementation phase (pre-implementation or postimplementation) on the other axis. From this table, a chi-square test of independence was
performed and a p-value calculated using α = .05 as the level of significance. A pooled VAE
incidence rate for all sites, which accounted for variations in ventilator-days between sites, was
also calculated for pre-intervention to post-intervention, and the process for hypothesis testing
repeated as it was performed for each individual site.
To analyze the second aim, staff compliance with the standardized oral assessment was
determined by utilizing the oral assessment form as a proxy for compliance. To determine the
strength of the association between staff compliance with the intervention and the change in
VAE incidence rate from pre-intervention to post-intervention, a Spearman’s ρ correlation
coefficient and a p-value calculated using α = .05 as the level of significance. Data were
analyzed using IBM’s Statistical Package for the Social Sciences (SPSS) software (SPSS,
2015).
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Data Analysis Plan
Question to be Answered
Did the incidence rate of VAE
decrease after implementation
of a standardized oral
assessment for adult patients on
mechanical ventilation?
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Measures
VAE incidence rate

Statistical Test
Chi-square test for independence

VAC incidence rate
IVAC incidence rate
PossVAP incidence rate

Was compliance with the
standardized oral assessment
associated with the incidence
rate of VAE in this population?

PrVAP incidence rate
Incidence rates at each site, as
above
% of vent-days with at least two
completed oral assessments on
data collection form

Spearman’s ρ

PREVENTING VAE

63

Human Subjects Protection
Institutional Review Board (IRB) approval was obtained from both the study site and
Valparaiso University prior to project implementation. Because this project utilized aggregated
system-level data instead of individual patient-level data, the project did not require the
acquisition of informed consent from individuals. Furthermore, since there was minimal risk
beyond that involved with receiving routine clinical care, and the informed consent document
would have been the only way to identify individual participants, this project was granted
“exempt” status from both IRBs. Facility infection preventionists, who served as the sources for
data on study outcomes, de-identified and aggregated outcomes data at the unit level prior to
these data being sent to the EBP project leader. All outcomes data were sent electronically
directly from the infection preventionist to the PI via e-mail communication. Each study site
assigned a specific place for staff nurses to submit the standardized oral assessment data
collection forms, which were kept in an opaque envelope or folder. The PI collected these forms
bi-weekly and transported them to a locked filing cabinet using a closeable binder.
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CHAPTER 4
FINDINGS

The purpose of this EBP project was to determine if an evidence-based oral care
assessment combined a with staff education program reduced the incidence of ventilator
associated events (VAE) among mechanically ventilated (whether via oral endotracheal
intubation, nasal endotracheal intubation, or tracheostomy) adults admitted into the intensive
care units at four Midwestern community hospitals over a four-month period, compared to
routine oral care practices over a prior nine-month period. This chapter will provide results from
the data analyses of the study.
In order to determine the effectiveness of the EBP project protocol, pre-intervention and
post-intervention VAE incidence rates and facility EBP protocol documentation compliance were
monitored on a monthly basis. Analyses of all variables are listed on Tables 4.1, 4.2, 4.3 and
4.4. The data from all four participating facilities were then pooled for the purpose of statistical
analysis using SPSS version 22 software.
Patient-Days and Ventilator-Days
This project utilized an administrative data set that included patient-days and ventilatordays at each facility. Pre and post-intervention data were collected over a pre-determined date
range at all participating sites. The pre-intervention period began January 1, 2014 and ended on
September 30, 2014. A one-month implementation phase was scheduled during October 2014.
Post-intervention data collection began on November 1, 2014 and continued until February 28,
2015.
Patient-days were calculated as the total number of patients in each intensive care unit
at midnight every day over each one-month period. Ventilator-days were calculated as the total
number of patients using mechanical ventilation in each intensive care unit at midnight every
day over each one-month period.
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Patient-days. A total of 13,050 patient-days were examined in this study (9,149 preintervention patient-days; 3,892 post-intervention patient-days). Table 4.1 provides details of the
distribution of patient-days at the 4 facilities.
Ventilator-days. Of the 13,050 patient-days, there were 4,892 ventilator-days (3,304
pre-intervention ventilator-days; 1,588 post-intervention ventilator-days). Table 4.1 provides
details of the distribution of ventilator-days at the 4 facilities.
Staff Compliance with Evidence-Based Practice
Daily completion of the Oral Health Assessment Tool was used as an indicator of staff
compliance with the standardized oral health assessment practice. Staff compliance was
calculated as the percentage of ventilator-days during the post-implementation phase with at
least two documented oral health assessments per day. Of 1,588 ventilator-days in the postimplementation phase, 399 had at least two documented oral health assessments (25.1%). The
staff compliance between facilities ranged from 2% to 70% (Table 4.2).
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Table 4.1
Patient-days and ventilator-days at study facilities
Facility

Patient-Days (%)

Pre-Implementation

Post-Implementation

Ventilator-Days (%)
Total

Pre-Implementation

Post-Implementation

Total

A

2356 (26)

824 (21)

3180

694 (21)

275 (17)

969

B

2166 (24)

1065 (27)

3231

582 (17)

343 (22)

925

C

1848 (20)

741 (19)

2589

650 (20)

271 (17)

921

D

2779 (30)

1271 (33)

4050

1378 (42)

699 (44)

2077

Pooled

9149 (100)

3901 (100)

13050

3304 (100)

1588 (100)

4892

Note: Administrative data set.
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Table 4.2
Staff compliance with evidence-based oral health assessment protocol
Facility

Correct Documentation

Ventilator-Days

Staff Compliance %

A

28

275

10.2

B

240

343

70

C

6

271

2.2

D

125

699

17.9

Total

399

1588

25.1

Criteria: At least two documented oral health assessments per day.
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Instrument Reliability
Two standardized, non-invasive, oral assessment tools (i.e., the Beck Oral Assessment
Scale [BOAS] and the Mucosa-Plaque Score [MPS]) were combined for this EBP into the Oral
Health Assessment Tool (Figure 1). Although the need to evaluate the psychometric properties
of the BOAS and the MPS have been discussed elsewhere (Beck, 1979; Henriksen,
Ambjornsen, & Axell, 1999; Silness, & Löe, 1964), no published results were found in the
literature search. Inter-rater reliability coefficients for the BOAS, MPS, and the Oral Health
Assessment Tool were calculated for the sample in this EBP project as .742, .592, and .824,
respectively (Table 4.3). This demonstrated that the reliability of the instrument combining the
MPS and BOAS was greater than the use of either scale alone. Validity of these scales was not
calculated as part of this EBP project.
Table 4.3
Internal consistency of instruments
Number of Items

Cronbach’s α

Beck Oral Assessment Scale (BOAS)

5

.742

Mucosa-Plaque Score (MPS)

2

.592

Oral Health Assessment Tool

7

.824

Instrument

Outcome Variables
VAE Incidence Rates. The PICOT question guiding this analysis asked, “Among
mechanically ventilated patients, how does the implementation of a standardized oral care
assessment guideline combined with a mandatory staff education program affect the incidence
of VAE when compared to standard care over a four month period?” VAE incidence rates varied
at all participating facilities (Table 4.4). However, during the pre-implementation phase, VAE
incidence rates at three participating facilities were less than 8.7 per 1,000 ventilator days.
Facility A exceeded that rate at 17.3 per 1,000 ventilator days. For comparison purposes, the
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pooled VAE rate for all sites was calculated. During the pre-implementation phase, the pooled
mean incidence rate for VAE across the four facilities was 9.99 per 1,000 ventilator-days (Table
4.4). During the post-implementation phase, VAE incidence rates continued to vary among the
four facilities (Table 4.4). The pooled mean incidence rate of VAE at all sites decreased to 8.2
per 1,000 ventilator-days in the post-implementation phase. However, this change was not
statistically significant.
Ventilator-associated pneumonia (VAP) was a relatively rare type of VAE in this sample,
which is consistent with the literature (CDC, 2014). There were no cases of confirmed VAP
during either the pre-implementation or the post-implementation phase. There were only four
cases of probable VAP during pre-implementation (all occurring at the same facility) and no
cases of probable VAP during post-implementation. Because the incidence of confirmed and
probable VAP was extremely low, statistical analysis of the VAP outcome variable was not
performed.
Figure 4.1
Pre and Post Changes in VAE Rates

VAE Incidence Rates per 1000
ventilator days

Changes in VAE Rates
25
21.8

20

17.3

15
10
6.9
5
0

7.7
5.8

8.7
5.7

3.7

9.99
8.2

Pre-Implemenation VAE
Rates
Post-Implementation VAE
Rates
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Table 4.4
Changes in VAE incidence rates
Facility
VAE
Frequency
(%)

Pre-Implementation
Ventilator- VAE Incidence
Days (%)
(per 1,000
ventilatordays)

VAE
Frequency
(%)

Post-Implementation
Ventilator VAE Incidence
-Days
(per 1,000
(%)
ventilatordays)

Change
in VAE
Incidence
rate

p-value

A

12 (36)

694 (21)

17.3

6 (46)

275 (17)

21.8

4.5

.73

B

4 (12)

582 (17)

6.9

2 (15)

343 (22)

5.8

-1.1

.85

C

5 (15)

650 (20)

7.7

1 (8)

271 (17)

3.7

-4

.49

D

12 (36)

1378 (42)

8.7

4 (31)

699 (44)

5.7

-3

.46

33 (100)

3304(100)

9.99

13 (100)

1588(10)

8.2

-1.8

.54

Inter-facility
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Significance of facility-specific VAE incidence rate changes. Changes in VAE
incidence rate were also analyzed within each facility (Table 4.4). Although reductions in VAE
incidence were observed at three of these facilities, and an increase in VAE incidence was
observed at one facility, these differences were not statistically significant.
Compliance with EBP intervention and post-implementation VAE incidence rate. A
post hoc analysis that determined the relationship between compliance with documentation of
the evidence-based oral health assessment protocol and changes in VAE incidence was
performed. Spearman’s rank correlation coefficient was calculated to assess this relationship.
Staff compliance with the oral health assessment protocol was positively correlated, but this
relationship was not statistically significant (r = .4, n = 4, p > .1).
Table 4.5
Significance of change in VAE rate and compliance rate, by facility
Facility
A

Staff Compliance rate %
(X Value)
10.2

Change in VAE Incidence
Rate (Y Value)
4.5

B

70

-1.1

C

2.2

-4

D

17.9

-3

Inter-facility

25.1

-1.8

The overall pooled results across all four study sites showed a moderate but observable
decrease in VAE incidence rate from the pre-intervention period to the post-intervention period.
This result was apparent in the site-specific results at all but one study location, Site A, where
the incidence rate increased. Notably, despite having had by far the highest compliance with
study documentation, Site B had the second least favorable change in VAE rate. This suggests
that any correlation between documentation compliance and the outcome of the intervention
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was weak. It may be instructive, in subsequent research, to investigate the relationship between
compliance and individual patient outcomes.
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Chapter 5
Discussion

The purpose of this EBP project was to answer the PICOT question: Among
mechanically ventilated patients, how does the implementation of an oral care assessment
guideline when combined with a staff education program, affect the incidence of ventilatorassociated events when compared to standard care over a four month period? This chapter will
discuss the findings presented in Chapter 4. This chapter will also discuss essential elements of
the Epidemiological Triangle of Infectious Disease and Everett Rogers’ Diffusion of Innovation
(DOI) framework (Rogers, 2005) that were used to integrate an evidence-based strategy to
decrease VAE rates among mechanically ventilated adults in the ICU setting. The applicability
and fit of the theoretical and EBP framework, strengths and weakness of the EBP projected and
implications for the future will also be addressed.
Explanation of Findings
It was important to determine the clinical feasibility and effectiveness of this EBP
project’s protocol. Therefore, descriptive statistics were used to assess facility specific, as well
as organizational pooled mean VAE rates and protocol adherence rates. The statistical software
SPSS version 22 was used was used to assess ordinal variables by utilizing the Chi Square test
to measure the strength of association between pre- implementation VAE rate and the postimplementation VAE rate.
This single-group pretest-posttest study utilized aggregate data that was collected in
accordance with NHSN guidelines by facility specific infection preventionist at four community
hospitals in the Midwest. De-identified data was reported to the principal investigator for
statistical analysis. The variables included: (a) patient days; (b) VAE count; (c) ventilator days;
(d) VAE rate; (e) ventilator device utilization (DU); (f) Ventilator-Associated Condition count
(VAC); (g) Infection-related Ventilator-Associated Complication (IVAC) count; and (h)
Possible/Probable ventilator associated pneumonia (P-VAP) count.
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Pre-implementation VAE data for this project were collected using a retrospective
approach by facility specific infection preventionists for the period from January 1, 2014 to
September 30, 2014. Post-intervention VAE data were collected on a monthly basis by facility
specific infection preventionists from November 1, 2014 until February 28, 2015. Descriptive
statistics were used to assess and compare facility specific, as well as cumulative pooled mean
data for all four sites. Comparisons of pre- and post-intervention VAE counts, VAE rates, patient
ventilator days, and changes in VAE incidence rates were discussed in Chapter 4 (Table 4.4).
As shown in Table 4.5, the pooled mean VAE incidence rate for the four facilities
declined by 1.8 cases per 100 ventilator-days in the post-implementation phase. However, this
drop was not statistically significant, Χ2 (1, N = 4,846) = .37, p = .54. Although most facilities
experienced decreased VAE rates, facility A experienced an increase in VAE rate of 4.5, which
was also not statistically significant, Χ2 (1, N = 951) = .22, p = .64. The study anticipated that low
staff engagement, as evidenced by lower documentation compliance would correspond to
higher VAE rates. Therefore, additional statistical analysis was performed by utilizing
Spearman’s rank correlation coefficient to determine if staff compliance with documentation of
the EBP intervention would be correlated with decreased VAE rates. Ultimately, the increased
VAE rate at Facility A proved unrelated to documentation compliance. Although the study did
not track staffing metrics, the author’s impression is that increased nurse turnover and use of
contingent labor at Facility A may have contributed to its outlier result. Whereas data does not
exist to draw firm conclusions about this outlier, evidence does exist to draw conclusions about
the lack of statistical significance of the results.
Post-implementation VAE rate changes may have been found not to be statistically
significant due to a variety of factors. First, there was a relatively small difference between the
pre-intervention and post-intervention VAE rates at the study sites. The VAE incidence rates at
most participating facilities were low to begin with and declined by 1.8 post-implementation. The
low rates decrease the detectability of changes. However, the findings are consistent with the
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published evidence (Dudeck et al., 2013a; 2013b; 2013c; Klompas et al., 2014; Klompas,
Kleinman, & Murphy, 2014; Lilly et al., 2014). Published evidence suggests that VAE incidence
rates have decreased as compared to previous VAP rates due to the specificity of the new
surveillance definition as proposed by the NHSN in 2013. Second, seasonal variability in the
VAE rates may have existed at all the participating sites. Seasonal staffing issues and seasonal
changes in the incidence of disease processes that contribute to the exacerbation of co-morbid
conditions may have contributed to the temporal variability. According to Lilly et al., (2014), the
new VAE surveillance definitions are less sensitive, are more resistant to manipulation, and do
not adequately account for temporality. Lastly, the aggregated data utilized in this study was
relatively small (n=4), when compared to larger, more comprehensive studies that include highrisk patient populations in academic medical centers and trauma centers. Larger, more robust
multi-facility studies that include teaching and specialty critical care units tend to have more
variability in VAE incidence rate changes (Dudeck et al., 2015; Herndon, 2012). Dudeck and
colleagues conducted a study in coordination with the NHSN that included critically ill patients
from over 3,000 hospitals of varying sizes that actively participate in the NHSN’s HAI
surveillance program. Critical care units, at larger teaching institutions, that care for high risk
patients with severely compromised bronchial-pulmonary air exchange, such as trauma and
burn critical care units, experience both an increased incidence and statistically significant
change in VAE rates (including VAP) when compared to the smaller critical care units, such as
the four enrolled in this study (Dudeck et al., 2015; Klompas et al., 2014; & Klompas et al.,
2015).
Compliance and Adherence to EBP intervention.
Compliance with the EBP intervention was tracked at all four facilities individually and
cumulatively (Table 4.2). Facility B had a 70% compliance rate and had the lowest preintervention VAE incidence rate among the four facilities (6.9 per 1000 ventilator days),
suggesting that nurses at facility B were already effective at preventing VAE before the project.
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On the other hand, facility A appeared to have the greatest challenge with VAE rates in the preimplementation period and was the only site to experience an increase in VAE rate in the postimplementation period. Possible contributing factors included high patient census, benefit and
staffing changes which may have impacted employee satisfaction leading to high turnover and
use of contingent staffing. Although the study did not include collection of staffing metrics, the
quality of care delivered to critically ill patients is understood to be sensitive to experience of the
nursing staff. At facility A, the investigator perceived a greater presence of contingent nurses
and nurses with limited critical care experience. However, these factors do not, on their own,
fully account for the lack of statistical significance in the results.
Whereas, facilities B, C, and D experienced decreases in VAE rates, the level of
analysis selected may have played the greatest role in hindering a finding of statistical
significance. Since results were aggregated for each facility over two periods, it was not
possible to control for patient specific risks or stratify data to reveal hidden trends. Future
research may benefit from performing analysis at the individual patient level with access to the
full range of data elements in the electronic medical record.
Furthermore, the use of aggregate data analysis effectively reduced the study’s sample
size from thousands of ventilator days to four sites. That small sample size reduced the ability of
the analysis to find statistical significance in the results. Nonetheless, various statistical
techniques were employed in the effort to draw meaningful conclusions from the study’s results.
Statistical analysis was performed using Spearman's ρ in order to determine if
compliance with the intervention’s documentation was correlated with a change in VAE rate.
Spearman's ρ was applied to two variables: facility compliance with documentation of the
evidence based intervention, and; changes in VAE rate following the intervention (Table 4.5).
Based on the results of the study, there was a moderate direct correlation between intervention
documentation compliance and differences in VAE rates, r (4)= .4, p< .05, but this correlation
was not statistically significant (p = .5). Therefore, these findings provide preliminary evidence of
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a trend towards reduced VAE rates using a staff education program to promote evidence-based
oral assessments for mechanically ventilated patients residing in intensive care units.
Applicability of the Theoretical Framework
Rogers’ Diffusion of Innovation (DOI) was selected as the guiding theoretical framework
for this EBP project. This well-established change model has been used in over 5,000 research
studies since it was first introduced in 1962 (Rogers, 2003), and it proved to be similarly useful
for this EBP project as well.
Fit of the EBP framework
Rogers’ Innovation Process in Organizations (2003, p. 421) consists of five stages within
two broader categories known as the initiation and implementation phases. The initiation phase
consists of the agenda-setting and matching stages where information gathering,
conceptualization, and pre planning occurs in order to define the organization’s problem and
facilitate the perceived need for an innovation or solution. During the initiation phase, the
principal investigator identified a clinical practice problem and assessed internal and external
factors in order to develop a solution to best fit the organization’s agenda. Issues of importance
to the organization such as priority, intended purpose and outcomes were ascertained from key
stakeholders. The PICOT format was utilized to initiate a literature search for all relevant
evidence. The search affirmed the need for incorporating standard oral assessments as part of
an evidence-based oral hygiene protocol for patients on mechanical ventilation to prevent VAEs
within the organization. Although current evidence outlined oral assessment mitigation
strategies to reduce or eliminate VAE, the organization had not been following those
recommendations.
The implementation phase consists of the redefining/ restructuring, clarifying and
routinizing stages. These three stages consist of all events, actions, and decisions involved in
getting an innovation adopted. Initially, during the redefining/ restructuring stage, the innovation
is incorporated into the organization. As implementation begins to occur, stakeholders become
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more comfortable with the new initiative and accommodation begins to occur as changes are
required and as barriers are identified. Adjustment may occur with both the organization and the
innovation. However, there is a narrow window of opportunity to make appropriate
modifications; thereafter, the innovation will be rapidly routinized and embedded within the
organization (Rogers, 2003, p. 424).
During the clarifying stage, the innovation becomes widespread across the entire
organization. Implementation processes should be monitored to ensure continued support and
stakeholder buy-in. In the case of this EBP project, changes had to be made to accommodate
the organizational agenda, stakeholder needs, and environmental functionality. Social
reconstruction often results during this stage. During this EBP project, key stakeholders had to
be reassured that the principle investigator would continue to monitor progress and clarify staff
concerns.
The routinizing stage occurs when the innovation becomes ingrained within the
organization’s regular activities. The successful adoption of an innovation signifies the end of
the innovation process. Sustainability of an innovation, also known as “institutionalization”, is
dependent on perceived need and on stakeholder participation in creating and implementing the
innovation (Goodman & Steckler, 1989; Rogers, 2003). Incremental change results, most often,
when innovation adoption occurs as a result of an authoritative decision. However,
transformational change occurs when collective innovation-decisions are made, due to wider
participation (Rogers, 2003, pg. 429).
Applying the theoretical framework. Rogers’ DOI framework is applicable to this EBP
project as it elucidates how adopters perceive new characteristics of a practice change or
innovation. Rogers’ (2003) framework guided the principle investigator in communicating and
prioritizing the innovation. The innovation for this EBP project was the implementation of a
standardized oral care assessment guideline in the critical care setting at four facilities. During
the knowledge stage of this EBP project, the principle investigator met with and spoke to facility
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stakeholders, unit leaders, and key opinion leaders within each unit at the participating facilities.
Key leaders included the regional director, department managers, and influential stakeholders
(i.e. clinical nurse specialists, IRB director, infection preventionists). Gaining early acceptance
and support from opinion leaders was crucial to the success of this study. Once formal approval
was garnered, the project leader was then able to embark upon communicating the innovation
within the organization’s social system.
The diffusion process was transmitted to critical care and intermediate care nursing staff
through the use of educational programs offered during the day and evening hours in order to
accommodate both the day and night shift staff. The educational presentation was also
uploaded onto YouTube and communicated to staff member via posters. Educational posters
and notebooks were strategically placed in all participating units. The educational programs
allowed for an open dialogue between the principle investigator and the nursing staff.
Interchanges of ideas, thoughts, and opinions were verbalized. Nonverbal forms of
communication were noted allowing both the investigator and staff to probe for a deeper
understanding of the problem, incidence of VAE, and the critical care unit culture. The
investigator controlled staff uncertainty by listening, educating, brainstorming, and sharing ideas
at each encounter. Ultimately, successful adoption of an innovation is reliant on how potential
adopters perceive the innovation (Rogers, 2003).
The DOI framework places adopters into five categories depending on how readily they
accept and incorporate innovative change initiatives. During the first two weeks of
implementation, the principle investigator attended morning and evening staff meetings to
explain the purpose of the EBP project and to underline the importance of the intervention to
patient outcomes. Targeting innovators and early adopters during the early stages of a change
effort is crucial to triggering the critical mass necessary to catalyze a change (Rogers, 2003).
Initiation of the innovation process was accomplished by familiarizing adopters with the
knowledge necessary to understand the purpose and function of the innovation.
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The innovative diffusion curve depicts late majority and laggards at the opposite end of
the spectrum from early adopters. Late majority individual are skeptical about innovation and
require peer pressure prior to initiating a change. Typically, late majority individuals adopt the
innovation after the majority of the adopters incorporate the practice change (Rogers, 2003).
Laggards are often deeply traditional, cautious, and suspicious of change according to Rogers
(2003). During the EBP implementation period, the investigator targeted educational resources,
through exchange of ideas, at these two groups comprised of highly experienced registered
nurses with longevity at their respective facilities.
During the persuasion stage, potential adopters must develop a positive outlook and
should view the innovation as beneficial. Five influential factors that are crucial to the successful
acceptance of an innovative process change include: relative advantage, compatibility,
complexity, trialability, and observability. Rogers (2003) contended that these characteristics
positively correlated with the rate of innovation adoption.
Relative advantage. Rogers’ DOI framework facilitates the adoption of the innovation by
conveying the relative advantage of the innovation (Rogers, 2003, p. 225). The framework
accounts for the healthcare setting as the unit of adoption and it facilitates the adoption of the
innovation by conveying potential benefits as improved outcomes relevant to the setting and
project goals (Rogers, 2003, p. 225). Past investigations have reported a positive relationship
between relative advantage and the rate of adoption (Rogers, 2003). As a result, the principal
investigator rounded at the four facilities on a biweekly bases and monitored documentation as
an indicator of project compliance to ensure the project’s momentum. The principal investigator
continued to educate, motivate, and remind staff that the EBP project was being implemented.
Phone calls were made to the day and night shift charge nurses, at all participating facilities, on
a twice weekly schedule.
In late November 2014, all four facilities implemented new pulmonary and ventilator
documentation profiles in the electronic medical record. All four facilities were implementing a
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pneumonia prevention initiative that paralleled this EBP project. As a result, when that initiative
began, staff was initially unsure if they had to continue documenting their oral health
assessments as outlined in this study. This required the EBP principal investigator to re-inform
facility staff members to continue with the implementation process.
Compatibility. Innovations must be compatible with the values, past experiences, and
needs of the adopter (Rogers, 2003). The innovation was compatible with the organization’s
mission to provide safe, cost effective, quality healthcare to promote good healthcare outcomes.
This EBP project was consistent with the organization’s goals, needs and workflow. Adopters
were comfortable with the innovation since it incorporated existing indigenous knowledge
systems. As a result this was not regarded as unnecessary or foreign. The staff nurses
perceived the innovation to be consistent with current practice and beneficial to the patients in
the form of improved oral health, infection control, and quality healthcare outcomes. Critical care
unit leadership was supportive of this project as it addressed current goals to reduce VAE rates
and variability. Therefore, this EBP project aligned well with the organization’s stewardship
initiative to reduce hospital acquired infections, particularly pneumonia, regionally.
Complexity. Complexity is described as “the degree to which an innovation is perceived
as relatively difficult to understand and use” (Rogers, 2003, p. 15). Innovations are easier to
adopt when they do not pose barriers to existing workflow processes (AHRQ, 2008, p. 2-222).
Registered nurses found the EBP intervention, as outlined by the BOAS and MPS, to be
intuitive and practical to their practice. Documentation, at all participating sites, was done via
electronic medical record. Consequently, the end-users (i.e. registered nurses), reported the
projects paper documentation method to be inconsistent with their workflow. The EBP
investigator alleviated concerns by consulting with end-users, project champions, and clinical
leadership regarding workflow optimization for this project. Staff nurses, project champions,
charge nurses, clinical nurse specialists and unit managers were instrumental in advising the
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EBP investigator regarding their workflow practices in order to reduce complexity and facilitate
adoption.
Complexity encompasses organizational barriers to change. One month postimplementation, a consulting group working at the corporate level of the organization,
implemented three quality improvement initiatives. One focused on VAP reduction. Since the
measures were synergistic with the EBP project, their workflow aligned well with the existing
documentation infrastructure. However, staff reported difficulty understanding project
distinctions and documentation requirements. Professional communication and team
collaboration presented synergistic opportunities for enhanced patient safety (AHRQ, 2008).
The principle investigator alleviated participant concerns through frequent communication.
Trialability. According to Rogers (2003), “trialability”, is the degree to which an innovation
may be experimented with on a limited basis” (p. 16). Trialability positively correlated with the
rate of adoption, especially among early adopters. As part of the implementation methodology,
the principle investigator allowed nursing staff to use and familiarize themselves with the BOAS
and MPS oral assessment tools. The tools were distributed to nursing staff on colored stationary
in an easy to read font. Documentation forms were also distributed and staff was encouraged to
practice documenting and familiarize themselves with the format prior to implementation. The
principle investigator noted that the site with the highest documentation compliance
institutionalized the Oral Health Assessment as part of everyday practice.
Observability. The last characteristic in DOI framework is observability. Rogers (2003)
defines observability as “the degree to which the results of an innovation are visible to others”
(p. 16). Role modeling and peer-to peer observation are two examples of how adopters can
motivate each other to adopt new innovations. This EBP intervention yielded observable results
immediately upon completion. Staff visualized the decrease in oral plaque within the patients’
oral cavity. Despite, the objective evidence in oral plaque removal, staff did not consistently
document the provision of oral care. However, VAE changes, unlike physical plaque removal,
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are not readily apparent to staff. The results of this study suggest that compliance with timely
oral care, when coupled with oral care assessments, may correlate with a decrease in VAE
incidence rates.
Decision, implementation, and confirmation make up the final three stages of Rogers
Innovation-Decision Process. During the decision stage, potential adopters determine either to
adopt or reject the implementation of a proposed innovation. As previously stated, this EBP
project was implemented at four intensive care units at four healthcare facilities that are owned
and operated by a larger health care organization. The decision to implement facility changes,
at the participating study sites, was at the discretion of two key organizational leaders. The two
leaders stated an interest in addressing a pressing issue, that being increases in VAE rates. As
a result, the principal investigator for this EBP project, gained support from organizational
stakeholders. Formal meetings were conducted with individuals in the following roles: (a)
regional director for critical care and infection control services at all four participating facilities;
(b) nursing unit managers, responsible for daily unit management; (c) clinical nurse specialists,
responsible for nursing education and unit support services; and (d) infection preventionists,
responsible for infection control and monitoring of infection related quality measures at specific
sites. IRB approval, to implement the EBP project, was granted after garnering support from key
opinion leaders.
The implementation stage initiates the innovation diffusion process within the clinical
environment. This was accomplished by developing a standardized oral care guideline that
incorporated existing oral care protocols, oral care procedures, and a standardized oral care
assessment tool. In essence, facility specific oral care practices and VAP bundle use were
incorporated into the innovation. Secondly, the provision for staff education concerning evidence
based oral care practices, oral care assessment, and the role of oral biofilm in the development
of VAEs, was discussed from an epidemiological perspective. The education program was
delivered to intensive care and intermediate care nursing staff on the day, evening, and night
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shifts. Presentation and related educational materials were made available in a variety of
formats to maximize the spread of the innovation. The presentation was delivered orally, via
PowerPoint presentation, and via abbreviated YouTube address and QR code displayed on a
poster. A project binder that included the purpose of the study, project outline, standardized oral
care guideline, BOAS and MPS tools, PowerPoint slides, and references, was delivered to each
participating intensive care unit.
Prior to implementation, discussions with opinion leaders revealed that there was VAE
variability across participating facilities. Support from unit leaders was eventually obtained. This
support was necessary to ensure project compliance within individual critical care units.
Innovation diffusion within an organization requires change management to facilitate and
encourage people to adopt initiatives. Corporate opinion leaders ensured that unit leaders were
implementing the oral care guideline at the study sites and documenting oral care practices on
the Oral Health Assessment Tool (Figure 4.2). Despite the additional oversight, documentation
compliance did not increase. This may be due to the implementation of a parallel VAP quality
improvement project by a consulting firm working with the organization. The consulting firm
integrated documentation changes within the EMR; thus, increasing adoption and
documentation compliance for their initiative. Workflow optimization was critical to encouraging
and sustaining innovation adoption within the clinical setting.
Strengths and weaknesses of the theoretical framework. Rogers’ Diffusion of
Innovations framework was adequate in guiding this EBP project. The DOI framework provides
effective strategies for implementing change and guiding the organizational adoption process.
Rogers’ framework assisted the principle investigator to identify influential leaders that would
facilitate access and acceptance of the practice change. For example, it was important to attain
support from key opinion leaders prior to initiating the implementation process. Influential
leaders within a hierarchical organization wield influence over subordinates; their support was
necessary for the success of this EBP project.
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A second strength of the DOI framework was identifying and understanding existing
workflow processes in place at each participating facility. Understanding and incorporating
workflow at each specific study site was essential to system participation and practice adoption.
Only then would participants appreciate the relative advantage of the new practice, as
supported by the literature, relative to standard practice. The evidence based practice change
was developed to be easy to understand, incorporating participants’ foundational knowledge to
streamline documentation efforts. The innovation was compatible with existing organizational
mission and values of providing an environment where innovation, technology, compassion and
knowledge converge to provide safe, quality healthcare services to all patients. Lastly, the
change was observable. Staff and patient family members provided positive feedback regarding
their perceptions of changes in the patient’s oral health status.
There were several limitations to using Rogers’ framework. While opinion leaders
encouraged and motivated staff members to utilize the change initiative, it was difficult to
determine whether individuals were actively embracing the change. The DOI framework does
not provide an adequately process for engaging late adopters and laggards. Continued
education, staff engagement and clinical support will encourage staff to learn about the inherent
benefit of maintaining this EBP initiative. Therefore, the principal investigator will reinforce
engagement by providing staff and the IRB with this EBP study’s results.
A limitation of Rogers’ Innovation-Decision Process is that it depicts a linear pathway.
However, the principal investigator iterated between the different stages throughout the study. In
particular, the stages of persuasion, implementation, and confirmation required iteration. For
example, the principal investigator continued to attend staff meetings, routinely rounded at all
study sites, and continued to provide educational reminders, educational in-services and
provided support for all staff nurses including new hires and temporary staff.
Applicability of the EBP framework
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Rogers’ Diffusion of Innovations-Decision Process (2003) guided the design and
implementation of this EBP project. The framework’s Innovation-Decision Process consists of
five phases that are designed to guide integration of research into practice.

Figure 5.1
Diffusion of Innovation Stages

Agenda-setting

Matching

Redefining/
Restructuring

Clarifying

Routinizing

Strengths and weakness of the EBP framework. Rogers’ Innovation Process (2003)
was a good fit for this EBP project, as it was rigorous enough to ensure the successful
implementation of the project. The EBP framework provided a five-stage guide that resulted in
the design and implementation of an EBP initiative. The principle investigator developed a
PICOT question, appraised the relevant literature, developed a practice guideline and
developed a nursing staff education program. Another strength of the EBP framework was that it
facilitated adaptive changes during the redefining and clarifying stages of the process. Rogers’
Innovation Process was the cornerstone of the entire project.
Limitations. A weakness of Rogers’ Innovation Process is that it does not adequately
address pro-innovation bias (Rogers, 2003). Such bias was evident at Facility B, where the
sense of urgency to adopt this change effort was pre-existing. This site was the first to commit
to the study, had the lowest pre-implementation VAE rate and extremely high documentation
compliance. In order to mitigate pro-innovation bias, the investigator invited participating
stakeholders to develop, critique, and provide feedback regarding the proposed innovation.
Another limitation is individual stakeholder blame bias for non-adoption. However, the
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investigator continued to support, educate, and reinforce the purpose of the change initiative in
an effort to mitigate potential limiting factors by individual stakeholders.
Rogers’ Innovation Process does not allow for the adequate evaluation of the innovation.
While the innovation’s process provides a mechanism for disseminating an innovation, it lacks
systematic criteria by which to evaluate contextual outcomes for the purpose of comparison.
Essentially, the innovation process fails to appraise the circumstances related to adoption or
non-adoption, as well as the consequences and rationales associated with incomplete or failed
adoptions (Meyer, 2004). However, it does provide some benchmarks for innovation diffusion
within a larger system.
Strengths and Limitations of the EBP project
Strengths. The study succeeded in several respects. First, the research and data
collected support the use of an evidence based oral health assessment during the provision of
oral care. Although results were not statistically significant, there is preliminary evidence that
adherence to oral care guidelines decreased VAE counts (including VAP). A second area of
strength was the use of the APN skill set. The APN provides value to the organization by
effectively using diverse skill sets to improve patient outcomes and healthcare quality, minimize
costs, and increase patient safety. This additional data contributes to the current evidence by
adding new knowledge regarding the utility of APN-led infection control practice changes (Goss
& Bryant, 2014). Lastly, the implementation of the innovative change benefited nursing staff and
the organization. The nursing staff in the critical care units expressed satisfaction with the
educational program as it enabled them to be more cognizant, not only of oral care practices,
but also, of the existence of microorganisms within the clinical environment. The staff’s
increased awareness empowered them to adopt the innovation and change their practices, thus
contributing to lower VAE rates.
This EBP project demonstrated that advanced practice nurses are in an ideal position to
coordinate evidence-based system-level interventions to reduce VAE. Furthermore, registered
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nurses and patients’ family members expressed satisfaction with this project. Nurse led
interventions are more likely to overcome adoption challenges due to nurses’ familiarity with the
organization’s culture, environment, clinical expertise, and access to key stakeholders.
Limitations. This EBP project utilized aggregate data from four distinct facilities with
different workflow processes and levels of staff engagement. Aggregated data is the
consolidation of data relating to multiple patients. This data is not patient specific, and therefore
cannot be traced back to a specific patient. The results of this study cannot be generalized at
the patient level. Aggregate data results are primarily utilized by organizations for process
improvement as quality indicators and for strategic planning.
Workflow processes at the multiple study sites impacted this study. Therefore, results
and compliance differed significantly. This, coupled with aggregated statistics and a sample size
of four facilities (n=4), was likely to have contributed to non-statistically significant findings
despite improved VAE frequencies.
Lastly, it was difficult to assess and maintain staff engagement given that all four
participating sites experienced varied confounding factors that affected their compliance and the
efficacy of this study. In order to maintain the engagement of some participants, it was
necessary to elicit repeated reaffirmations of support from senior leaders. Furthermore, other
initiatives within the organization had the potential to introduce confusion regarding study
methods. This was apparent when staff notified the principal investigator that the standardized
oral health assessment form had been uploaded into the EMR. Subsequent inquiry revealed
that the organization had made revisions to its VAP prevention documentation in the electronic
medical record. These revisions were unrelated to this study and utilized different data
elements. In future rounding sessions, the need to continue use of the Oral Health Assessment
Tool was reinforced. However, since the Oral Health Assessment Tool was not mandatory,
compliance rates dropped at a site that had not yet institutionalized the change. Due to nurses’
use of their organization’s patient specific documentation method, that data was not available
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for analysis. Only results documented on the paper based standardized oral assessment form
were included in this study. This may have limited the power of the assessment tool to detect
compliance with the overall intervention.
Implications for the Future
Practice. Evidence based practice changes integrate research and clinical expertise
with the primary goal of improving patient and healthcare outcomes. The advanced practice
nurses’ multifaceted skill set and clinical expertise lay the foundation for an increased role within
healthcare organizations. As clinical educators, consultants and providers, APNs can use their
strong leadership abilities to enable transformational change. APNs are in a prime position to
promote and implement EBP recommendation into clinical practice and can play a pivotal role in
the adoption and uptake of new innovative practices. Future research may involve developing a
systems level approach to increase oral care documentation rates. Given ongoing and
impending national healthcare reforms, advanced practice nurses could help healthcare
organizations adapt by developing and guiding change management initiatives.
Theory. The epidemiologic triangle and Rogers’ DOI Framework and Innovation
Process were useful in guiding the development and implementation of this EBP project.
However, Rogers’ Innovation Process was of limited utility when evaluating the project
outcomes. Future theory development should explore why the translation of research to practice
is lagging, especially in the area of VAE prevention, and develop strategies to improve
compliance with EBP recommendations. Additionally, future theory development needs to
address needs from the family’s perspective. Theory that integrates the family unit provides
context to the problem and may even serve to encourage practice change and adoption.
Research. A review of the literature revealed thousands of research articles describing
the implications of VAE development. However, relatively few articles evaluated barriers to
implementation such as standards and procedures related to the provision of oral care and VAE
prevention, staff compliance, and staff feedback regarding change initiatives. Research that
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focuses on increasing individual, group, and system adoption of innovation needs to be
undertaken. Future research should focus on developing strategies for the successful adoption
of and compliance with, the provision of evidence based oral care and oral health assessment
documentation. Additionally, future research could incorporate patient level data as well as the
patient’s or family’s perspective. In so doing, researchers could access the richer context that
may provide greater depth and understanding of change initiatives and their adoption within the
critical care setting.
Education. After an innovation is adopted, practice changes are affirmed and become
routinized into everyday practice. VAE prevention requires commitment and continued staff
education at all levels. Therefore a multidisciplinary approach and transparency should be
encouraged within organizations. Educating new personnel during orientation and providing
yearly skills training is imperative to sustaining a long lasting practice change. Additionally, an
intra-organizational team based approach should be used to foster organizational cohesiveness.
Multidisciplinary approaches can alleviate facility specific barriers that interfere with the adoption
of current EBP guidelines.
Conclusion
This EBP project provided useful information for critical care nurses, advanced practice
nurses, nursing managers, and other healthcare providers regarding the strength of the
evidence published in the literature. Based on the evidence presented, practice guidelines can
be utilized to implement meaningful change within the ICU setting. The effects of oral hygiene
care on the incidence of hospital-acquired infections, including VAE, among critically ill patients
are important. Timely oral assessments, mechanical brushing, use of CHG solutions,
maintaining appropriate infection control measure during the provision of care, and staff
educations, will reduce the incidence of ventilator associated conditions (Koemam et al., 2006;
ICSI, 2011; Shi et al., 2013).
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Although statistical significance was not found, this study provided preliminary evidence
that routine oral assessment and timely intervention in mechanically ventilated patients are
useful components of comprehensive oral care practices to prevent or reduce the incidence of
VAE.
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